{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "id": "kIc15opVTZ7y"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "import json\n",
        "import ast"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "trials_df = pd.read_csv(\"./data/trials_parsed.csv\")"
      ],
      "metadata": {
        "id": "HeWxpTtuTcqY"
      },
      "execution_count": 23,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "trials_df"
      ],
      "metadata": {
        "id": "_NzOlkmGTctB",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "222e9470-7f97-426c-e795-b6630e0a36a9"
      },
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "         NCT_ID                                              Title  \\\n",
              "0   NCT00009971  Fenretinide in Treating Patients With Recurren...   \n",
              "1   NCT03836352  Study of an Immunotherapeutic, DPX-Survivac, i...   \n",
              "2   NCT04421352  Safety and Tolerability Evaluation of Low-dose...   \n",
              "3   NCT01774526  Molecular Epidemiology of Lung Adenocarcinoma ...   \n",
              "4   NCT01780675                   Hippocampus Avoidance PCI vs PCI   \n",
              "..          ...                                                ...   \n",
              "58  NCT06400472  A Study of LY4170156 in Participants With Sele...   \n",
              "59  NCT01944137                  Improving Care After Chemotherapy   \n",
              "60  NCT01780675                   Hippocampus Avoidance PCI vs PCI   \n",
              "61  NCT05369312  Phase 1 Study of BPI-442096 in Advanced Solid ...   \n",
              "62  NCT07106528  Organoid-guided vs Topotecan Therapy in Relaps...   \n",
              "\n",
              "                                       Official_Title                 Status  \\\n",
              "0   Phase II Trial Of Fenretinide (NSC-374551; IND...              COMPLETED   \n",
              "1   A Phase 2, Open-label, Multicenter, Study of a...  ACTIVE_NOT_RECRUITING   \n",
              "2   A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose...              COMPLETED   \n",
              "3   Molecular Epidemiology of Lung Adenocarcinoma ...                UNKNOWN   \n",
              "4   Prophylactic Cranial Irradiation With or Witho...              COMPLETED   \n",
              "..                                                ...                    ...   \n",
              "58  A First-in-Human, Phase 1a/1b Trial to Assess ...             RECRUITING   \n",
              "59                  Improving Care After Chemotherapy              COMPLETED   \n",
              "60  Prophylactic Cranial Irradiation With or Witho...              COMPLETED   \n",
              "61  Phase 1 Study of BPI-442096 in Advanced Solid ...                UNKNOWN   \n",
              "62  Organoid-Based Drug Sensitivity Model Guided P...     NOT_YET_RECRUITING   \n",
              "\n",
              "    Start_Date Primary_Completion      Study_Type          Phases  Enrollment  \\\n",
              "0      2000-11            2005-09  INTERVENTIONAL          PHASE2          32   \n",
              "1   2018-12-21         2023-12-31  INTERVENTIONAL          PHASE2         184   \n",
              "2   2021-01-12         2023-12-22  INTERVENTIONAL          PHASE1          11   \n",
              "3      2010-12            2016-12  INTERVENTIONAL             NaN          40   \n",
              "4      2013-04         2019-04-01  INTERVENTIONAL          PHASE3         168   \n",
              "..         ...                ...             ...             ...         ...   \n",
              "58  2024-05-20            2027-02  INTERVENTIONAL          PHASE1         495   \n",
              "59     2013-09            2014-11  INTERVENTIONAL             NaN         120   \n",
              "60     2013-04         2019-04-01  INTERVENTIONAL          PHASE3         168   \n",
              "61     2022-06         2024-05-01  INTERVENTIONAL          PHASE1         230   \n",
              "62     2025-08            2027-12  INTERVENTIONAL  PHASE2, PHASE3         128   \n",
              "\n",
              "                                           Conditions  ...   Min_Age  \\\n",
              "0                                         Lung Cancer  ...  18 Years   \n",
              "1   Ovarian Cancer, Hepatocellular Carcinoma, Non-...  ...  18 Years   \n",
              "2                     Relapsed Small Cell Lung Cancer  ...  18 Years   \n",
              "3                                         Lung Cancer  ...  21 Years   \n",
              "4                 Small Cell Lung Cancer, Lung Cancer  ...  18 Years   \n",
              "..                                                ...  ...       ...   \n",
              "58  Ovarian Neoplasms, Endometrial Neoplasms, Uter...  ...  18 Years   \n",
              "59  Non-small Cell Lung Cancer, Colorectal Cancer,...  ...  18 Years   \n",
              "60                Small Cell Lung Cancer, Lung Cancer  ...  18 Years   \n",
              "61  Solid Tumor, Non-small Cell Lung Cancer, Pancr...  ...  18 Years   \n",
              "62  Extensive-stage Small Cell Lung Cancer (ES-SCL...  ...  18 Years   \n",
              "\n",
              "     Max_Age                                 Lead_Sponsor  \\\n",
              "0        NaN              National Cancer Institute (NCI)   \n",
              "1        NaN  ImmunoVaccine Technologies, Inc. (IMV Inc.)   \n",
              "2   75 Years                       CStone Pharmaceuticals   \n",
              "3        NaN      National University Hospital, Singapore   \n",
              "4        NaN             The Netherlands Cancer Institute   \n",
              "..       ...                                          ...   \n",
              "58       NaN                        Eli Lilly and Company   \n",
              "59       NaN               Massachusetts General Hospital   \n",
              "60       NaN             The Netherlands Cancer Institute   \n",
              "61  75 Years              Betta Pharmaceuticals Co., Ltd.   \n",
              "62       NaN        Peking Union Medical College Hospital   \n",
              "\n",
              "                                        Brief_Summary  \\\n",
              "0   Phase II trial to study the effectiveness of f...   \n",
              "1   This study will assess the safety and efficacy...   \n",
              "2   A Phase Ia/Ib Safety and Tolerability Evaluati...   \n",
              "3   Lung Cancer continues to be the major cause of...   \n",
              "4   Using Intensity Modulated radiotherapy it is p...   \n",
              "..                                                ...   \n",
              "58  The purpose of this study is to find out wheth...   \n",
              "59  The main purpose of this study is to examine c...   \n",
              "60  Using Intensity Modulated radiotherapy it is p...   \n",
              "61  A first-in-human study to evaluate the safety,...   \n",
              "62  This study aims to provide personalized treatm...   \n",
              "\n",
              "                                          Eligibility  \\\n",
              "0   DISEASE CHARACTERISTICS: * Histologically or c...   \n",
              "1   Key Inclusion Criteria: * Subjects with advanc...   \n",
              "2   Inclusion Criteria: 1. Patients with histologi...   \n",
              "3   Inclusion Criteria: * Asian ethnicity * Age \\>...   \n",
              "4   Inclusion Criteria: * \\- Small Cell Lung Cance...   \n",
              "..                                                ...   \n",
              "58  Inclusion Criteria: * Have one of the followin...   \n",
              "59  Inclusion Criteria: * Adult (age 18 or older) ...   \n",
              "60  Inclusion Criteria: * \\- Small Cell Lung Cance...   \n",
              "61  Inclusion Criteria: * Signed informed consent;...   \n",
              "62  Inclusion Criteria: 1. Aged 18 years or older....   \n",
              "\n",
              "                                     Primary_Measures  \\\n",
              "0                                                 NaN   \n",
              "1   Efficacy as measured by objective response rat...   \n",
              "2   To determine the recommended radiation dose an...   \n",
              "3   Descriptive study of our patients with lung ad...   \n",
              "4                              neurocognitive decline   \n",
              "..                                                ...   \n",
              "58  Phase 1a: To determine the recommended phase 2...   \n",
              "59  Change from baseline (i.e. first chemotherapy ...   \n",
              "60                             neurocognitive decline   \n",
              "61  The adverse events (AEs) | Determine the recom...   \n",
              "62                    Progression-Free Survival (PFS)   \n",
              "\n",
              "                                   Secondary_Measures  \\\n",
              "0                                                 NaN   \n",
              "1   Objective response rate | Duration of response...   \n",
              "2   Incidence of Adverse Events (AE) and Dose-Limi...   \n",
              "3                                                 NaN   \n",
              "4                                              safety   \n",
              "..                                                ...   \n",
              "58  To characterize the pharmacokinetics (PK) prop...   \n",
              "59  Change from baseline (i.e. first chemotherapy ...   \n",
              "60                                             safety   \n",
              "61  Cmax | Tmax | t1/2 | AUC0-t | the objective re...   \n",
              "62  Overall Survival (OS) | Objective Response Rat...   \n",
              "\n",
              "                                        Interventions elig_len  \\\n",
              "0                                    DRUG:fenretinide     1815   \n",
              "1   OTHER:DPX-Survivac | DRUG:Cyclophosphamide | D...     2335   \n",
              "2                                         DRUG:CS1001     1904   \n",
              "3   OTHER:Characterise the molecular epidemiology ...      535   \n",
              "4   RADIATION:Radiation Prophylactic Cranial Irrad...      741   \n",
              "..                                                ...      ...   \n",
              "58  DRUG:LY4170156 | DRUG:bevacizumab | DRUG:carbo...     1251   \n",
              "59                         OTHER:Nursing Intervention      531   \n",
              "60  RADIATION:Radiation Prophylactic Cranial Irrad...      741   \n",
              "61                                    DRUG:BPI-442096     1902   \n",
              "62  DRUG:Organoid Drug Sensitivity Testing-Guided ...     2304   \n",
              "\n",
              "                                     eligibility_json  \n",
              "0   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "1   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "2   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "3   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "4   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "..                                                ...  \n",
              "58  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "59  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "60  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "61  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "62  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "\n",
              "[63 rows x 21 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-96ba758a-2d61-4156-b85d-92c42b44562c\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>NCT_ID</th>\n",
              "      <th>Title</th>\n",
              "      <th>Official_Title</th>\n",
              "      <th>Status</th>\n",
              "      <th>Start_Date</th>\n",
              "      <th>Primary_Completion</th>\n",
              "      <th>Study_Type</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>...</th>\n",
              "      <th>Min_Age</th>\n",
              "      <th>Max_Age</th>\n",
              "      <th>Lead_Sponsor</th>\n",
              "      <th>Brief_Summary</th>\n",
              "      <th>Eligibility</th>\n",
              "      <th>Primary_Measures</th>\n",
              "      <th>Secondary_Measures</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>elig_len</th>\n",
              "      <th>eligibility_json</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>NCT00009971</td>\n",
              "      <td>Fenretinide in Treating Patients With Recurren...</td>\n",
              "      <td>Phase II Trial Of Fenretinide (NSC-374551; IND...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2000-11</td>\n",
              "      <td>2005-09</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>32</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>National Cancer Institute (NCI)</td>\n",
              "      <td>Phase II trial to study the effectiveness of f...</td>\n",
              "      <td>DISEASE CHARACTERISTICS: * Histologically or c...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DRUG:fenretinide</td>\n",
              "      <td>1815</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>NCT03836352</td>\n",
              "      <td>Study of an Immunotherapeutic, DPX-Survivac, i...</td>\n",
              "      <td>A Phase 2, Open-label, Multicenter, Study of a...</td>\n",
              "      <td>ACTIVE_NOT_RECRUITING</td>\n",
              "      <td>2018-12-21</td>\n",
              "      <td>2023-12-31</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>184</td>\n",
              "      <td>Ovarian Cancer, Hepatocellular Carcinoma, Non-...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ImmunoVaccine Technologies, Inc. (IMV Inc.)</td>\n",
              "      <td>This study will assess the safety and efficacy...</td>\n",
              "      <td>Key Inclusion Criteria: * Subjects with advanc...</td>\n",
              "      <td>Efficacy as measured by objective response rat...</td>\n",
              "      <td>Objective response rate | Duration of response...</td>\n",
              "      <td>OTHER:DPX-Survivac | DRUG:Cyclophosphamide | D...</td>\n",
              "      <td>2335</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NCT04421352</td>\n",
              "      <td>Safety and Tolerability Evaluation of Low-dose...</td>\n",
              "      <td>A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2021-01-12</td>\n",
              "      <td>2023-12-22</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>11</td>\n",
              "      <td>Relapsed Small Cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>75 Years</td>\n",
              "      <td>CStone Pharmaceuticals</td>\n",
              "      <td>A Phase Ia/Ib Safety and Tolerability Evaluati...</td>\n",
              "      <td>Inclusion Criteria: 1. Patients with histologi...</td>\n",
              "      <td>To determine the recommended radiation dose an...</td>\n",
              "      <td>Incidence of Adverse Events (AE) and Dose-Limi...</td>\n",
              "      <td>DRUG:CS1001</td>\n",
              "      <td>1904</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>NCT01774526</td>\n",
              "      <td>Molecular Epidemiology of Lung Adenocarcinoma ...</td>\n",
              "      <td>Molecular Epidemiology of Lung Adenocarcinoma ...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2010-12</td>\n",
              "      <td>2016-12</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NaN</td>\n",
              "      <td>40</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>21 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>National University Hospital, Singapore</td>\n",
              "      <td>Lung Cancer continues to be the major cause of...</td>\n",
              "      <td>Inclusion Criteria: * Asian ethnicity * Age \\&gt;...</td>\n",
              "      <td>Descriptive study of our patients with lung ad...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>OTHER:Characterise the molecular epidemiology ...</td>\n",
              "      <td>535</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>NCT01780675</td>\n",
              "      <td>Hippocampus Avoidance PCI vs PCI</td>\n",
              "      <td>Prophylactic Cranial Irradiation With or Witho...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2013-04</td>\n",
              "      <td>2019-04-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE3</td>\n",
              "      <td>168</td>\n",
              "      <td>Small Cell Lung Cancer, Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>The Netherlands Cancer Institute</td>\n",
              "      <td>Using Intensity Modulated radiotherapy it is p...</td>\n",
              "      <td>Inclusion Criteria: * \\- Small Cell Lung Cance...</td>\n",
              "      <td>neurocognitive decline</td>\n",
              "      <td>safety</td>\n",
              "      <td>RADIATION:Radiation Prophylactic Cranial Irrad...</td>\n",
              "      <td>741</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>58</th>\n",
              "      <td>NCT06400472</td>\n",
              "      <td>A Study of LY4170156 in Participants With Sele...</td>\n",
              "      <td>A First-in-Human, Phase 1a/1b Trial to Assess ...</td>\n",
              "      <td>RECRUITING</td>\n",
              "      <td>2024-05-20</td>\n",
              "      <td>2027-02</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>495</td>\n",
              "      <td>Ovarian Neoplasms, Endometrial Neoplasms, Uter...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Eli Lilly and Company</td>\n",
              "      <td>The purpose of this study is to find out wheth...</td>\n",
              "      <td>Inclusion Criteria: * Have one of the followin...</td>\n",
              "      <td>Phase 1a: To determine the recommended phase 2...</td>\n",
              "      <td>To characterize the pharmacokinetics (PK) prop...</td>\n",
              "      <td>DRUG:LY4170156 | DRUG:bevacizumab | DRUG:carbo...</td>\n",
              "      <td>1251</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>59</th>\n",
              "      <td>NCT01944137</td>\n",
              "      <td>Improving Care After Chemotherapy</td>\n",
              "      <td>Improving Care After Chemotherapy</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2013-09</td>\n",
              "      <td>2014-11</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NaN</td>\n",
              "      <td>120</td>\n",
              "      <td>Non-small Cell Lung Cancer, Colorectal Cancer,...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Massachusetts General Hospital</td>\n",
              "      <td>The main purpose of this study is to examine c...</td>\n",
              "      <td>Inclusion Criteria: * Adult (age 18 or older) ...</td>\n",
              "      <td>Change from baseline (i.e. first chemotherapy ...</td>\n",
              "      <td>Change from baseline (i.e. first chemotherapy ...</td>\n",
              "      <td>OTHER:Nursing Intervention</td>\n",
              "      <td>531</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>60</th>\n",
              "      <td>NCT01780675</td>\n",
              "      <td>Hippocampus Avoidance PCI vs PCI</td>\n",
              "      <td>Prophylactic Cranial Irradiation With or Witho...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2013-04</td>\n",
              "      <td>2019-04-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE3</td>\n",
              "      <td>168</td>\n",
              "      <td>Small Cell Lung Cancer, Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>The Netherlands Cancer Institute</td>\n",
              "      <td>Using Intensity Modulated radiotherapy it is p...</td>\n",
              "      <td>Inclusion Criteria: * \\- Small Cell Lung Cance...</td>\n",
              "      <td>neurocognitive decline</td>\n",
              "      <td>safety</td>\n",
              "      <td>RADIATION:Radiation Prophylactic Cranial Irrad...</td>\n",
              "      <td>741</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>61</th>\n",
              "      <td>NCT05369312</td>\n",
              "      <td>Phase 1 Study of BPI-442096 in Advanced Solid ...</td>\n",
              "      <td>Phase 1 Study of BPI-442096 in Advanced Solid ...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2022-06</td>\n",
              "      <td>2024-05-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>230</td>\n",
              "      <td>Solid Tumor, Non-small Cell Lung Cancer, Pancr...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>75 Years</td>\n",
              "      <td>Betta Pharmaceuticals Co., Ltd.</td>\n",
              "      <td>A first-in-human study to evaluate the safety,...</td>\n",
              "      <td>Inclusion Criteria: * Signed informed consent;...</td>\n",
              "      <td>The adverse events (AEs) | Determine the recom...</td>\n",
              "      <td>Cmax | Tmax | t1/2 | AUC0-t | the objective re...</td>\n",
              "      <td>DRUG:BPI-442096</td>\n",
              "      <td>1902</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>62</th>\n",
              "      <td>NCT07106528</td>\n",
              "      <td>Organoid-guided vs Topotecan Therapy in Relaps...</td>\n",
              "      <td>Organoid-Based Drug Sensitivity Model Guided P...</td>\n",
              "      <td>NOT_YET_RECRUITING</td>\n",
              "      <td>2025-08</td>\n",
              "      <td>2027-12</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2, PHASE3</td>\n",
              "      <td>128</td>\n",
              "      <td>Extensive-stage Small Cell Lung Cancer (ES-SCL...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Peking Union Medical College Hospital</td>\n",
              "      <td>This study aims to provide personalized treatm...</td>\n",
              "      <td>Inclusion Criteria: 1. Aged 18 years or older....</td>\n",
              "      <td>Progression-Free Survival (PFS)</td>\n",
              "      <td>Overall Survival (OS) | Objective Response Rat...</td>\n",
              "      <td>DRUG:Organoid Drug Sensitivity Testing-Guided ...</td>\n",
              "      <td>2304</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>63 rows Ã— 21 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-96ba758a-2d61-4156-b85d-92c42b44562c')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-96ba758a-2d61-4156-b85d-92c42b44562c button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-96ba758a-2d61-4156-b85d-92c42b44562c');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-3b07ac89-985c-4dba-9f5c-bc11fec510f8\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-3b07ac89-985c-4dba-9f5c-bc11fec510f8')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-3b07ac89-985c-4dba-9f5c-bc11fec510f8 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_c8f8a36d-c646-4dd6-bd0e-eadbdf38911a\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('trials_df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_c8f8a36d-c646-4dd6-bd0e-eadbdf38911a button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('trials_df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "trials_df"
            }
          },
          "metadata": {},
          "execution_count": 4
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "trials_df = trials_df.drop_duplicates(subset=['NCT_ID'], keep='first').reset_index(drop=True)"
      ],
      "metadata": {
        "id": "n8i2NqNMTcvx"
      },
      "execution_count": 5,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "trials_df"
      ],
      "metadata": {
        "id": "KH18I3hcTcyg",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "c0f9ff84-ab80-4e13-97c1-7c392a18fa6b"
      },
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "         NCT_ID                                              Title  \\\n",
              "0   NCT00009971  Fenretinide in Treating Patients With Recurren...   \n",
              "1   NCT03836352  Study of an Immunotherapeutic, DPX-Survivac, i...   \n",
              "2   NCT04421352  Safety and Tolerability Evaluation of Low-dose...   \n",
              "3   NCT01774526  Molecular Epidemiology of Lung Adenocarcinoma ...   \n",
              "4   NCT01780675                   Hippocampus Avoidance PCI vs PCI   \n",
              "5   NCT03231111  The Effectiveness of Using Preventive Multimed...   \n",
              "6   NCT00447421  A Study to Treat Small Cell Lung Cancer With a...   \n",
              "7   NCT00084487  Rebeccamycin Analog as Second-Line Therapy in ...   \n",
              "8   NCT05958199  A Study of NPX267 for Subjects With Solid Tumo...   \n",
              "9   NCT02015416  A Phase 1 Trial of NY-ESO-1 With GLA-SE in Pat...   \n",
              "10  NCT06607185  A Study of the Pan-KRAS Inhibitor LY4066434 in...   \n",
              "11  NCT06725225  Machine Learning for Predicting and Managing Q...   \n",
              "12  NCT06079970         Confocal Laser Endomicroscopy VERification   \n",
              "13  NCT02117024  A Phase 2 Study of Viagenpumatucel-L (HS-110) ...   \n",
              "14  NCT00494026  Chemotherapy and Radiotherapy to Treat Patient...   \n",
              "15  NCT06963502  A Phase Ib Study of HS-10370 in Addition to Ot...   \n",
              "16  NCT00663689  Efficacy of Erlotinib for Brain Metastasis of ...   \n",
              "17  NCT02772107  Temozolomide as Maintenance Therapy Following ...   \n",
              "18  NCT03313544  Evolution of the Heart Function When Monitorin...   \n",
              "19  NCT02349412  Early Palliative Care With Standard Care or St...   \n",
              "20  NCT07090499  A Study to Learn About the Study Medicine Call...   \n",
              "21  NCT01075399  Study of [F 18]HX4 Positron Emission Tomograph...   \n",
              "22  NCT04964960                         Pembro+Chemo in Brain Mets   \n",
              "23  NCT01951469  Gefitinib With or Without Chemotherapy in Brai...   \n",
              "24  NCT00094003    Study of NS-9 in Patients With Liver Metastases   \n",
              "25  NCT03699956  RRx-001 Sequentially With a Platinum Doublet o...   \n",
              "26  NCT00046787  Efficacy and Safety Study of OSI-211 (Liposoma...   \n",
              "27  NCT02606149  Truthful Information on Chemotherapy and Its I...   \n",
              "28  NCT06838208  Tislelizumab Combined With Chemotherapy and Re...   \n",
              "29  NCT03778814  TCR-T Cell Immunotherapy of Lung Cancer and Ot...   \n",
              "30  NCT03613753  Irinotecan Plus Lobaplatin Versus Irinotecan i...   \n",
              "31  NCT05369312  Phase 1 Study of BPI-442096 in Advanced Solid ...   \n",
              "32  NCT02805530  Radical Treatment of Synchronous Oligometastat...   \n",
              "33  NCT02669719  Cellular Immunotherapy Synergize Chemotherapy ...   \n",
              "34  NCT02318277  A Study of Epacadostat (INCB024360) in Combina...   \n",
              "35  NCT00910676  Study About Preventive Treatment of Folliculit...   \n",
              "36  NCT03871205  Neoantigen-primed DC Vaccines Therapy for Refr...   \n",
              "37  NCT04311710  A Study Evaluating the Drug Levels of Iplimuma...   \n",
              "38  NCT07006727  Phase I Study of [225Ac]Ac-ETN029 in Patients ...   \n",
              "39  NCT04306900  TTX-030 in Combination With Immunotherapy and/...   \n",
              "40  NCT01487499  Bronchoscopic Intratumoral Chemotherapy for Sm...   \n",
              "41  NCT05450692  A Phase III Study of Ceralasertib Plus Durvalu...   \n",
              "42  NCT01064466  Pharmacogenomics ANDA SNP Clinical Study - Eto...   \n",
              "43  NCT00375245  Rapamycin With Grapefruit Juice for Advanced M...   \n",
              "44  NCT00475657  Pemetrexed and Cisplatin as Treatment in Small...   \n",
              "45  NCT01944137                  Improving Care After Chemotherapy   \n",
              "46  NCT03501056  Study of Activated Cytokine-induced Killer Arm...   \n",
              "47  NCT00759824  A Phase II Study of Doxorubicin, Cyclophospham...   \n",
              "48  NCT00621361  Phase I Safety and Tolerability Study of Cedir...   \n",
              "49  NCT06749691       Liposomal Irinotecan and Apatinib in ES-SCLC   \n",
              "50  NCT01588821        Cabozantinib in Advanced Solid Malignancies   \n",
              "51  NCT03361228  A Study to Evaluate the Safety, Tolerability, ...   \n",
              "52  NCT02281214  NGS Genome Analysis in Personalisation of Lung...   \n",
              "53  NCT05538130  A Study to Learn About the Study Medicine Call...   \n",
              "54  NCT00967577  177Lu-J591 Antibody in Patients With Nonprosta...   \n",
              "55  NCT02200081  Randomized Study of Maintenance Therapy With M...   \n",
              "56  NCT00570401  Dasatinib in Treating Patients With Advanced L...   \n",
              "57  NCT00496860  Safety and Efficacy Study of ALT-801 to Treat ...   \n",
              "58  NCT06400472  A Study of LY4170156 in Participants With Sele...   \n",
              "59  NCT07106528  Organoid-guided vs Topotecan Therapy in Relaps...   \n",
              "\n",
              "                                       Official_Title                 Status  \\\n",
              "0   Phase II Trial Of Fenretinide (NSC-374551; IND...              COMPLETED   \n",
              "1   A Phase 2, Open-label, Multicenter, Study of a...  ACTIVE_NOT_RECRUITING   \n",
              "2   A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose...              COMPLETED   \n",
              "3   Molecular Epidemiology of Lung Adenocarcinoma ...                UNKNOWN   \n",
              "4   Prophylactic Cranial Irradiation With or Witho...              COMPLETED   \n",
              "5   The Effectiveness of Using Preventive Multimed...                UNKNOWN   \n",
              "6   Phase I/II Study of Concurrent Cisplatin, Peme...             TERMINATED   \n",
              "7   Phase II Trial of XL119 (Rebeccamycin Analogue...             TERMINATED   \n",
              "8   A Phase 1a/1b, Dose-Escalation/Dose-Expansion ...              SUSPENDED   \n",
              "9   A Phase 1 Open Label, Multicenter, Multiple As...              COMPLETED   \n",
              "10  A Phase 1a/1b Study of the Pan-KRAS Inhibitor ...             RECRUITING   \n",
              "11  Development of a Machine Learning-Based Risk P...     NOT_YET_RECRUITING   \n",
              "12  Bronchoscopy With and Without Needle-based Con...             RECRUITING   \n",
              "13  A Phase 2, Multicenter, Randomized Study to Ev...             TERMINATED   \n",
              "14  Phase II Study of Concurrent Carboplatin, Peme...             TERMINATED   \n",
              "15  A Phase Ib Study Evaluating the Safety, Tolera...     NOT_YET_RECRUITING   \n",
              "16  A Phase II Study of Erlotinib in Benefitted Pa...                UNKNOWN   \n",
              "17                                                NaN                UNKNOWN   \n",
              "18  Evolution of the Heart Function When Monitorin...                UNKNOWN   \n",
              "19  Randomized Study of Early Palliative Care Inte...              COMPLETED   \n",
              "20  A Phase 1 Open-label Study to Investigate PF-0...             RECRUITING   \n",
              "21  A Pilot, Phase II , Open Label, Nonrandomized,...              COMPLETED   \n",
              "22  Phase II Investigation of Use of CNS Active Pe...             TERMINATED   \n",
              "23  Multicenter Phase III Study of Gefitinib Mono-...                UNKNOWN   \n",
              "24  A Phase I, Open-Label, Dose Escalation Study o...              COMPLETED   \n",
              "25  A Phase 3, Controlled, Open-label, Randomized ...             TERMINATED   \n",
              "26  Phase II Study to Determine the Efficacy of OS...              COMPLETED   \n",
              "27  Impact of a Truthful Information Concerning Ch...              COMPLETED   \n",
              "28  Efficacy and Safety of Tislelizumab Combined W...             RECRUITING   \n",
              "29  TCR-T Cells Targeting Cancer Cells for Immunot...             RECRUITING   \n",
              "30  A Randomized Phase II Trial of Irinotecan Plus...                UNKNOWN   \n",
              "31  Phase 1 Study of BPI-442096 in Advanced Solid ...                UNKNOWN   \n",
              "32  Radical Treatment of Synchronous Oligometastat...              COMPLETED   \n",
              "33  A Randomized Phase II Study to Evaluate Effica...                UNKNOWN   \n",
              "34  A Phase 1/2 Study Exploring the Safety, Tolera...              COMPLETED   \n",
              "35  Phase II Multicentric Study About Preventive T...              COMPLETED   \n",
              "36  A Phase I Study on the Safety and the Efficacy...                UNKNOWN   \n",
              "37  A Phase 1/2 Pharmacokinetic Multi-tumor Study ...             TERMINATED   \n",
              "38  A Phase I, Open-label, Multi-center Study to E...             RECRUITING   \n",
              "39  Phase 1/1b Study to Evaluate the Safety and Ac...              COMPLETED   \n",
              "40  Bronchoscopic Intratumoral Chemotherapy for Sm...             TERMINATED   \n",
              "41  A Phase III, Open-label, Randomised, Multicent...  ACTIVE_NOT_RECRUITING   \n",
              "42  Explore the Relationship Between Single Nucleo...  ACTIVE_NOT_RECRUITING   \n",
              "43  A Phase Ib Study Administering Rapamycin (Siro...              COMPLETED   \n",
              "44  Phase II Study of Pemetrexed Plus Cisplatin in...             TERMINATED   \n",
              "45                  Improving Care After Chemotherapy              COMPLETED   \n",
              "46  Phase II Randomized Comparison Clinical Trial ...              WITHDRAWN   \n",
              "47  A Phase II Study of Doxorubicin, Cyclophospham...              COMPLETED   \n",
              "48  A Phase I, Multi-Centre, Open-Label, Dose Sele...              COMPLETED   \n",
              "49  Study of Liposomal Irinotecan Combined with Ap...             RECRUITING   \n",
              "50  Phase II Trial of Cabozantinib (XL184) in Pati...              COMPLETED   \n",
              "51  An Open-Label, Multicenter, Nonrandomized, Dos...             TERMINATED   \n",
              "52  Genome Analysis by Next Generation Sequencing ...              COMPLETED   \n",
              "53  A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-077...             RECRUITING   \n",
              "54  177Lu Radiolabeled Monoclonal Antibody HuJ591-...              COMPLETED   \n",
              "55  Randomized Clinical Study of Maintenance Thera...              COMPLETED   \n",
              "56  A Phase 2 Trial of Dasatinib in Patients With ...              COMPLETED   \n",
              "57  Phase I Study of ALT-801 in Patients With Prog...              COMPLETED   \n",
              "58  A First-in-Human, Phase 1a/1b Trial to Assess ...             RECRUITING   \n",
              "59  Organoid-Based Drug Sensitivity Model Guided P...     NOT_YET_RECRUITING   \n",
              "\n",
              "    Start_Date Primary_Completion      Study_Type          Phases  Enrollment  \\\n",
              "0      2000-11            2005-09  INTERVENTIONAL          PHASE2          32   \n",
              "1   2018-12-21         2023-12-31  INTERVENTIONAL          PHASE2         184   \n",
              "2   2021-01-12         2023-12-22  INTERVENTIONAL          PHASE1          11   \n",
              "3      2010-12            2016-12  INTERVENTIONAL             NaN          40   \n",
              "4      2013-04         2019-04-01  INTERVENTIONAL          PHASE3         168   \n",
              "5   2017-07-25         2018-07-01  INTERVENTIONAL             NaN          60   \n",
              "6      2007-02            2008-05  INTERVENTIONAL  PHASE1, PHASE2           9   \n",
              "7      2004-04            2008-04  INTERVENTIONAL          PHASE2          21   \n",
              "8   2023-07-21         2025-09-20  INTERVENTIONAL          PHASE1         131   \n",
              "9      2013-11            2016-12  INTERVENTIONAL          PHASE1          13   \n",
              "10  2024-10-21            2030-01  INTERVENTIONAL          PHASE1         750   \n",
              "11  2025-01-01         2025-12-01  INTERVENTIONAL             NaN         200   \n",
              "12  2023-10-18         2025-10-18  INTERVENTIONAL             NaN         208   \n",
              "13     2014-07            2017-12  INTERVENTIONAL          PHASE2          66   \n",
              "14     2007-09            2008-10  INTERVENTIONAL          PHASE2           4   \n",
              "15  2025-05-30         2028-12-31  INTERVENTIONAL          PHASE1         762   \n",
              "16     2008-03            2011-03  INTERVENTIONAL          PHASE2          45   \n",
              "17     2015-12            2017-06  INTERVENTIONAL  PHASE2, PHASE3         132   \n",
              "18  2018-04-09            2024-10  INTERVENTIONAL          PHASE4          50   \n",
              "19  2015-06-25         2017-07-03  INTERVENTIONAL          PHASE3         405   \n",
              "20  2025-08-20         2028-07-08  INTERVENTIONAL          PHASE1         310   \n",
              "21     2010-02            2011-05  INTERVENTIONAL          PHASE2          50   \n",
              "22  2022-05-19         2023-06-19  INTERVENTIONAL          PHASE2           3   \n",
              "23     2016-01            2022-06  INTERVENTIONAL          PHASE3         160   \n",
              "24     2002-09                NaN  INTERVENTIONAL          PHASE1          20   \n",
              "25  2018-12-24         2022-08-11  INTERVENTIONAL          PHASE3          18   \n",
              "26     2002-09                NaN  INTERVENTIONAL          PHASE2          47   \n",
              "27  2016-07-15         2020-10-15  INTERVENTIONAL             NaN         123   \n",
              "28  2025-02-25         2027-03-01  INTERVENTIONAL          PHASE2          56   \n",
              "29  2018-12-01         2029-12-30  INTERVENTIONAL          PHASE1          30   \n",
              "30  2018-06-01         2020-06-01  INTERVENTIONAL          PHASE2          72   \n",
              "31     2022-06         2024-05-01  INTERVENTIONAL          PHASE1         230   \n",
              "32     2015-06            2018-08  INTERVENTIONAL             NaN          36   \n",
              "33     2016-01            2017-01  INTERVENTIONAL          PHASE2          70   \n",
              "34  2015-01-05         2019-08-28  INTERVENTIONAL  PHASE1, PHASE2         176   \n",
              "35     2007-10            2009-03  INTERVENTIONAL          PHASE2          30   \n",
              "36  2019-04-01         2020-06-30  INTERVENTIONAL          PHASE1          30   \n",
              "37  2020-06-25         2021-01-14  INTERVENTIONAL          PHASE1          21   \n",
              "38  2025-10-16         2031-06-17  INTERVENTIONAL          PHASE1          96   \n",
              "39  2020-03-30         2022-11-30  INTERVENTIONAL          PHASE1         185   \n",
              "40     2011-12            2015-03  INTERVENTIONAL          PHASE3           4   \n",
              "41  2022-09-15         2025-10-06  INTERVENTIONAL          PHASE3         594   \n",
              "42  2025-07-16         2026-11-18  INTERVENTIONAL  PHASE2, PHASE3         600   \n",
              "43     2006-09            2009-05  INTERVENTIONAL          PHASE1          41   \n",
              "44     2007-10            2008-04  INTERVENTIONAL          PHASE2           5   \n",
              "45     2013-09            2014-11  INTERVENTIONAL             NaN         120   \n",
              "46  2018-03-27         2020-05-25  INTERVENTIONAL          PHASE2           0   \n",
              "47     2008-09            2013-12  INTERVENTIONAL          PHASE2          64   \n",
              "48     2008-02            2009-08  INTERVENTIONAL          PHASE1          62   \n",
              "49  2024-12-28            2027-12  INTERVENTIONAL          PHASE2          30   \n",
              "50     2012-06            2017-01  INTERVENTIONAL          PHASE2          37   \n",
              "51  2018-03-01         2019-03-30  INTERVENTIONAL  PHASE1, PHASE2           5   \n",
              "52  2014-10-24         2014-11-17  INTERVENTIONAL             NaN         165   \n",
              "53  2022-11-30         2027-02-02  INTERVENTIONAL          PHASE1         124   \n",
              "54     2009-07            2018-06  INTERVENTIONAL          PHASE1          20   \n",
              "55     2014-03            2016-11  INTERVENTIONAL          PHASE2         103   \n",
              "56     2006-06            2011-09  INTERVENTIONAL          PHASE2          22   \n",
              "57     2007-05            2009-10  INTERVENTIONAL          PHASE1          26   \n",
              "58  2024-05-20            2027-02  INTERVENTIONAL          PHASE1         495   \n",
              "59     2025-08            2027-12  INTERVENTIONAL  PHASE2, PHASE3         128   \n",
              "\n",
              "                                           Conditions  ...   Min_Age  \\\n",
              "0                                         Lung Cancer  ...  18 Years   \n",
              "1   Ovarian Cancer, Hepatocellular Carcinoma, Non-...  ...  18 Years   \n",
              "2                     Relapsed Small Cell Lung Cancer  ...  18 Years   \n",
              "3                                         Lung Cancer  ...  21 Years   \n",
              "4                 Small Cell Lung Cancer, Lung Cancer  ...  18 Years   \n",
              "5                                         Lung Cancer  ...  20 Years   \n",
              "6   Small Cell Lung Cancer, Carcinoma, Small Cell,...  ...  18 Years   \n",
              "7   Extensive Stage Small Cell Lung Cancer, Limite...  ...  18 Years   \n",
              "8                       Metastatic Malignant Neoplasm  ...  18 Years   \n",
              "9   Melanoma, Ovarian Cancer, Sarcoma, Non-small C...  ...  18 Years   \n",
              "10  Pancreatic Ductal Adenocarcinoma, Non-small Ce...  ...  18 Years   \n",
              "11                               Lung Cancer Patients  ...  18 Years   \n",
              "12  Lung Cancer, Lung Neoplasm Malignant, Carcinom...  ...  18 Years   \n",
              "13                         Non Small Cell Lung Cancer  ...  18 Years   \n",
              "14                             Small Cell Lung Cancer  ...  18 Years   \n",
              "15  Advanced Solid Tumors, Colorectal Cancer, Non-...  ...  18 Years   \n",
              "16       Non-Small Cell Lung Cancer, Brain Metastases  ...  18 Years   \n",
              "17             Extensive-stage Small Cell Lung Cancer  ...  18 Years   \n",
              "18              Melanoma, Non-small Cell, Lung Cancer  ...  18 Years   \n",
              "19  Liver Cancer, Anxiety Disorder, Depression, Sm...  ...  18 Years   \n",
              "20  Advanced/Metastatic Solid Tumors, Bladder Canc...  ...  18 Years   \n",
              "21  Head and Neck Cancer, Lung Cancer, Liver Cance...  ...  18 Years   \n",
              "22  Lung Cancer, Lung Cancer Metastatic, Brain Can...  ...  18 Years   \n",
              "23  Non-small Cell Lung Cancer, Brain Metastases, ...  ...  18 Years   \n",
              "24  Liver Neoplasms, Neoplasm Metastasis, Local Ne...  ...  18 Years   \n",
              "25                         Carcinoma, Small Cell Lung  ...  18 Years   \n",
              "26                        SCLC, Carcinoma, Small Cell  ...  18 Years   \n",
              "27                               Stage IV Lung Cancer  ...  18 Years   \n",
              "28   Extensive-stage Small Cell Lung Cancer (ES-SCLC)  ...  18 Years   \n",
              "29      Nonsmall Cell Lung Cancer, Solid Tumor, Adult  ...  18 Years   \n",
              "30                             Small-cell Lung Cancer  ...  18 Years   \n",
              "31  Solid Tumor, Non-small Cell Lung Cancer, Pancr...  ...  18 Years   \n",
              "32  Carcinoma, Non-Small-Cell Lung, Synchronous Ne...  ...  18 Years   \n",
              "33                         Non Small Cell Lung Cancer  ...  18 Years   \n",
              "34  Solid Tumors, Head and Neck Cancer, Lung Cance...  ...  18 Years   \n",
              "35  Metastatic Colorectal Cancer, Non-Small-Cell L...  ...  18 Years   \n",
              "36  Carcinoma, Non-Small Cell Lung, Carcinoma, Sma...  ...  18 Years   \n",
              "37                                              Tumor  ...  18 Years   \n",
              "38  Small Cell Lung Carcinoma, Large Cell Neuroend...  ...  18 Years   \n",
              "39                                 Solid Tumor, Adult  ...  18 Years   \n",
              "40                             Small Cell Lung Cancer  ...       NaN   \n",
              "41  Advanced or Metastatic Non-Small Cell Lung Cancer  ...  18 Years   \n",
              "42                             Small Cell Lung Cancer  ...  24 Years   \n",
              "43                        Tumors, Neoplasm Metastasis  ...  18 Years   \n",
              "44                             Small Cell Lung Cancer  ...  18 Years   \n",
              "45  Non-small Cell Lung Cancer, Colorectal Cancer,...  ...  18 Years   \n",
              "46                               Advanced Lung Cancer  ...  18 Years   \n",
              "47                          Small Cell Lung Carcinoma  ...  18 Years   \n",
              "48                                        Lung Cancer  ...  18 Years   \n",
              "49             Small Cell Lung Cancer Extensive Stage  ...  18 Years   \n",
              "50  Lung Cancer, Solid Tumor (Not Breast or Prosta...  ...  18 Years   \n",
              "51                                       Solid Tumors  ...  18 Years   \n",
              "52                                        Lung Cancer  ...  18 Years   \n",
              "53  Melanoma, Glioma, Thyroid Cancer, Non-Small Ce...  ...  16 Years   \n",
              "54  Kidney Cancer, Head and Neck Cancer, Breast Ca...  ...  18 Years   \n",
              "55                             Small Cell Lung Cancer  ...  18 Years   \n",
              "56                                        Lung Cancer  ...  18 Years   \n",
              "57                Progressive Metastatic Malignancies  ...  18 Years   \n",
              "58  Ovarian Neoplasms, Endometrial Neoplasms, Uter...  ...  18 Years   \n",
              "59  Extensive-stage Small Cell Lung Cancer (ES-SCL...  ...  18 Years   \n",
              "\n",
              "      Max_Age                                       Lead_Sponsor  \\\n",
              "0         NaN                    National Cancer Institute (NCI)   \n",
              "1         NaN        ImmunoVaccine Technologies, Inc. (IMV Inc.)   \n",
              "2    75 Years                             CStone Pharmaceuticals   \n",
              "3         NaN            National University Hospital, Singapore   \n",
              "4         NaN                   The Netherlands Cancer Institute   \n",
              "5    80 Years                National Taiwan University Hospital   \n",
              "6         NaN                              Eli Lilly and Company   \n",
              "7         NaN                    National Cancer Institute (NCI)   \n",
              "8         NaN                       NextPoint Therapeutics, Inc.   \n",
              "9    80 Years  Immune Design, a subsidiary of Merck & Co., In...   \n",
              "10        NaN                              Eli Lilly and Company   \n",
              "11        NaN  Second Affiliated Hospital of Zunyi Medical Un...   \n",
              "12        NaN  Amsterdam University Medical Centers (UMC), Lo...   \n",
              "13        NaN                                     Heat Biologics   \n",
              "14        NaN                              Eli Lilly and Company   \n",
              "15        NaN            Jiangsu Hansoh Pharmaceutical Co., Ltd.   \n",
              "16        NaN             Guangdong Provincial People's Hospital   \n",
              "17   75 Years                       Chinese PLA General Hospital   \n",
              "18        NaN          Assistance Publique Hopitaux De Marseille   \n",
              "19        NaN           Alliance for Clinical Trials in Oncology   \n",
              "20        NaN                                             Pfizer   \n",
              "21        NaN                          Siemens Molecular Imaging   \n",
              "22   85 Years                           John L. Villano, MD, PhD   \n",
              "23   75 Years                             Sun Yat-sen University   \n",
              "24        NaN                                    NS Pharma, Inc.   \n",
              "25   79 Years                                    EpicentRx, Inc.   \n",
              "26        NaN                                Astellas Pharma Inc   \n",
              "27        NaN            Assistance Publique - HÃ´pitaux de Paris   \n",
              "28        NaN                   Anhui Provincial Cancer Hospital   \n",
              "29   75 Years  Second Affiliated Hospital of Guangzhou Medica...   \n",
              "30   70 Years                                         ShengFa Su   \n",
              "31   75 Years                    Betta Pharmaceuticals Co., Ltd.   \n",
              "32        NaN       Instituto Nacional de Cancerologia de Mexico   \n",
              "33        NaN                            Shanghai Chest Hospital   \n",
              "34        NaN                                 Incyte Corporation   \n",
              "35        NaN                               Centre Oscar Lambret   \n",
              "36   70 Years                         Shenzhen People's Hospital   \n",
              "37        NaN                               Bristol-Myers Squibb   \n",
              "38  100 Years                           Novartis Pharmaceuticals   \n",
              "39  110 Years                        Trishula Therapeutics, Inc.   \n",
              "40        NaN                              University of Florida   \n",
              "41  130 Years                                        AstraZeneca   \n",
              "42   64 Years  Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigat...   \n",
              "43        NaN                              University of Chicago   \n",
              "44        NaN                              Eli Lilly and Company   \n",
              "45        NaN                     Massachusetts General Hospital   \n",
              "46   75 Years                    Fuda Cancer Hospital, Guangzhou   \n",
              "47        NaN                 European Lung Cancer Working Party   \n",
              "48        NaN                                        AstraZeneca   \n",
              "49   75 Years  Second Affiliated Hospital, School of Medicine...   \n",
              "50        NaN                     Massachusetts General Hospital   \n",
              "51        NaN                                 Incyte Corporation   \n",
              "52        NaN                    Centre Georges Francois Leclerc   \n",
              "53        NaN                                             Pfizer   \n",
              "54        NaN        Weill Medical College of Cornell University   \n",
              "55        NaN                                         Mologen AG   \n",
              "56  120 Years             Memorial Sloan Kettering Cancer Center   \n",
              "57        NaN                                   Altor BioScience   \n",
              "58        NaN                              Eli Lilly and Company   \n",
              "59        NaN              Peking Union Medical College Hospital   \n",
              "\n",
              "                                        Brief_Summary  \\\n",
              "0   Phase II trial to study the effectiveness of f...   \n",
              "1   This study will assess the safety and efficacy...   \n",
              "2   A Phase Ia/Ib Safety and Tolerability Evaluati...   \n",
              "3   Lung Cancer continues to be the major cause of...   \n",
              "4   Using Intensity Modulated radiotherapy it is p...   \n",
              "5   The Effectiveness of Using Preventive Multimed...   \n",
              "6   The purpose of this study is to determine the ...   \n",
              "7   Drugs used in chemotherapy, such as rebeccamyc...   \n",
              "8   NPX267 is an antibody drug targeting the inhib...   \n",
              "9   This is a Phase I, multi-center, multiple asce...   \n",
              "10  The main purpose of the study is to assess whe...   \n",
              "11  The goal of this study is to explore whether h...   \n",
              "12  The goal of this multi-center randomized clini...   \n",
              "13  Determine whether viagenpumatucel-L combined w...   \n",
              "14  This is a multicenter, phase II, open-label tr...   \n",
              "15  This is a Phase Ib study that will evaluate th...   \n",
              "16  This is a non-randomized open-label uncontroll...   \n",
              "17  Temozolomide may delay progression in sequence...   \n",
              "18  Prospective, monocentric clinical study. Patie...   \n",
              "19  The study intervention consists of the early i...   \n",
              "20  The purpose of the study is to explore the saf...   \n",
              "21  This pilot phase II study is designed as a tes...   \n",
              "22  The goal of this study is to evaluate whether ...   \n",
              "23  This is a multi-center phase III randomized co...   \n",
              "24  This study is to investigate the safety of NS-...   \n",
              "25  This Phase 3 study aims to find out whether RR...   \n",
              "26  The purpose of this study is to determine whet...   \n",
              "27  Patients with metastatic cancer have a substan...   \n",
              "28  To explore the efficacy and safety of Tisleliz...   \n",
              "29  Tumor organoids and TILs (and/or peripheral T ...   \n",
              "30  This randomized phase II study compare surviva...   \n",
              "31  A first-in-human study to evaluate the safety,...   \n",
              "32  Non-small cell lung cancer (NSCLC) is the most...   \n",
              "33  This is a randomized, open-label, phaseâ…¡ study...   \n",
              "34  The purpose of this study is to explore the sa...   \n",
              "35  Patients will receive local prophylactic treat...   \n",
              "36  Various of immunotherapies are now widely appl...   \n",
              "37  A study evaluating the drug levels of ipilimum...   \n",
              "38  The purpose of this study is to evaluate the s...   \n",
              "39  This is a phase 1/1b study of TTX-030 in combi...   \n",
              "40  This project proposes to use bronchoscopic int...   \n",
              "41  This study will assess the efficacy and safety...   \n",
              "42  Explore the relationship between drug target t...   \n",
              "43  The purpose of this study is to determine the ...   \n",
              "44  The purpose of this study is to determine if c...   \n",
              "45  The main purpose of this study is to examine c...   \n",
              "46  This is a phase II Randomized comparison clini...   \n",
              "47  The primary aim of this study is to determine ...   \n",
              "48  This study is to assess the safety and tolerab...   \n",
              "49  The purpose of this study is to observe the ef...   \n",
              "50  This research study is a Phase II clinical tri...   \n",
              "51  The purpose of this study is to assess the saf...   \n",
              "52  The identification of driver mutations in the ...   \n",
              "53  The purpose of this clinical trial is to learn...   \n",
              "54  The purpose of this study is to evaluate chang...   \n",
              "55  Evaluation of efficacy and safety of MGN1703 a...   \n",
              "56  RATIONALE: Dasatinib may stop the growth of tu...   \n",
              "57  This is a Phase 1, open-labeled, non-randomize...   \n",
              "58  The purpose of this study is to find out wheth...   \n",
              "59  This study aims to provide personalized treatm...   \n",
              "\n",
              "                                          Eligibility  \\\n",
              "0   DISEASE CHARACTERISTICS: * Histologically or c...   \n",
              "1   Key Inclusion Criteria: * Subjects with advanc...   \n",
              "2   Inclusion Criteria: 1. Patients with histologi...   \n",
              "3   Inclusion Criteria: * Asian ethnicity * Age \\>...   \n",
              "4   Inclusion Criteria: * \\- Small Cell Lung Cance...   \n",
              "5   Inclusion Criteria: 1. Patients older than 20 ...   \n",
              "6   Inclusion Criteria: * Measurable disease with ...   \n",
              "7   Inclusion Criteria: * Diagnosis of small cell ...   \n",
              "8   Inclusion Criteria: * Histologically or cytolo...   \n",
              "9   Inclusion Criteria: * Confirmed diagnosis of m...   \n",
              "10  Inclusion Criteria: * Have evidence of KRAS G1...   \n",
              "11  Inclusion Criteria: 1. Histologically diagnose...   \n",
              "12  Inclusion Criteria: 1. â‰¥18 years of age 2. Sus...   \n",
              "13  Inclusion Criteria: * Non-small cell lung aden...   \n",
              "14  Inclusion Criteria: * Histologic and/or cytolo...   \n",
              "15  Inclusion Criteria: * Men or women greater tha...   \n",
              "16  Inclusion criteria: 1. Histological or cytolog...   \n",
              "17  Inclusion Criteria: * Cytologically and/or his...   \n",
              "18  Inclusion Criteria: patients treated with nivo...   \n",
              "19  Study Patient Participant Eligibility Requirem...   \n",
              "20  Inclusion Criteria: * 18 years of age or older...   \n",
              "21  Inclusion Criteria: * Patient is \\>18 years an...   \n",
              "22  Inclusion Criteria: * Non-small cell lunch can...   \n",
              "23  Inclusion Criteria: 1. Patient who was confirm...   \n",
              "24  Inclusion Criteria: * Male and female at least...   \n",
              "25  Inclusion Criteria: 1. Age â‰¥ 18 and \\< 80 year...   \n",
              "26  Inclusion Criteria: * Confirmed recurrent smal...   \n",
              "27  Inclusion Criteria: * stage IV lung cancer, hi...   \n",
              "28  Inclusion Criteria: 1. Ageâ‰¥18 years old, male ...   \n",
              "29  Inclusion Criteria: 1. patients with advanced ...   \n",
              "30  Inclusion Criteria: * Relapsed SCLC * Etoposid...   \n",
              "31  Inclusion Criteria: * Signed informed consent;...   \n",
              "32  Inclusion Criteria: * Pathology diagnosis of n...   \n",
              "33  Inclusion Criteria: 1. Histologically or cytol...   \n",
              "34  Inclusion Criteria: * Male or female subjects,...   \n",
              "35  Inclusion Criteria: * Indication of Cetuximab ...   \n",
              "36  Inclusion Criteria: * Age â‰¥18 years â‰¤ 70 years...   \n",
              "37  For more information regarding Bristol-Myers S...   \n",
              "38  Inclusion Criteria: * Age â‰¥ 18 years old * Pat...   \n",
              "39  Abbreviated Inclusion Criteria: 1. Age 18 year...   \n",
              "40  Inclusion Criteria: Competent adult English sp...   \n",
              "41  Inclusion Criteria: * Histologically or cytolo...   \n",
              "42  * Select 600 Small Cell Lung Cancer Patients w...   \n",
              "43  Inclusion Criteria: * Histologically confirmed...   \n",
              "44  Inclusion Criteria: * Histologic or cytologic ...   \n",
              "45  Inclusion Criteria: * Adult (age 18 or older) ...   \n",
              "46  Inclusion Criteria: * 18-75 years old * The pa...   \n",
              "47  Inclusion Criteria: * Histological or cytologi...   \n",
              "48  Inclusion Criteria: * Cancer diagnosis and sta...   \n",
              "49  Inclusion Criteria: 1. Age range of 18-75 year...   \n",
              "50  Inclusion Criteria: * Histologic or cytologic ...   \n",
              "51  Inclusion Criteria: * For Phase 1, subjects wi...   \n",
              "52  Inclusion Criteria: * patients of bronchial ad...   \n",
              "53  Inclusion Criteria: * Diagnosis of advanced/me...   \n",
              "54  Inclusion Criteria: * Histologically, or cytol...   \n",
              "55  1. Male and female patients with extensive dis...   \n",
              "56  DISEASE CHARACTERISTICS: * Pathologically conf...   \n",
              "57  ENTRY CRITERIA: DISEASE CHARACTERISTICS: * Loc...   \n",
              "58  Inclusion Criteria: * Have one of the followin...   \n",
              "59  Inclusion Criteria: 1. Aged 18 years or older....   \n",
              "\n",
              "                                     Primary_Measures  \\\n",
              "0                                                 NaN   \n",
              "1   Efficacy as measured by objective response rat...   \n",
              "2   To determine the recommended radiation dose an...   \n",
              "3   Descriptive study of our patients with lung ad...   \n",
              "4                              neurocognitive decline   \n",
              "5                                          skindex-29   \n",
              "6   Phase 1: Maximum Tolerated Dose | Phase 2: Ove...   \n",
              "7   Objective Response Rate Estimated as the Propo...   \n",
              "8   Incidence of dose limiting toxicity | Incidenc...   \n",
              "9                             Safety and tolerability   \n",
              "10  Number of Participants with Dose-limiting Toxi...   \n",
              "11                    EORTC QLQ C30 | EORTC QLQ LC-13   \n",
              "12         Diagnostic yield (intermediate definition)   \n",
              "13                              Overall Survival (OS)   \n",
              "14  Proportion of Patients With a Complete or Part...   \n",
              "15  Number of Participants with Adverse Event(s) (...   \n",
              "16  Time of asymptomatic brain metastasis turn int...   \n",
              "17                     PFS of the maintenance therapy   \n",
              "18               systolic pulmonary arterial pressure   \n",
              "19  Change in Quality of Life (QOL) From Baseline ...   \n",
              "20  Incidence of Treatment Emergent Adverse Events...   \n",
              "21  Reproducibility of [F18]HX4 PET Imaging in Mea...   \n",
              "22                               Disease Control Rate   \n",
              "23        iPFS(intracranial progression free survival   \n",
              "24                                                NaN   \n",
              "25                          Progression Free Survival   \n",
              "26                                                NaN   \n",
              "27  Number of patients receiving chemotherapy in t...   \n",
              "28                    Progression Free Survival (PFS)   \n",
              "29     Number of Patients with Dose Limiting Toxicity   \n",
              "30                      Objective Response Rate (ORR)   \n",
              "31  The adverse events (AEs) | Determine the recom...   \n",
              "32                                   Overall survival   \n",
              "33                          Progression-free survival   \n",
              "34  Phase 1 : Number of Treatment-Emergent Adverse...   \n",
              "35  To reduce by 30 % the frequency of folliculiti...   \n",
              "36  Incidence of Treatment-Emergent Adverse Events...   \n",
              "37  Part 1 Arm A: Average concentration of ipilimu...   \n",
              "38  Number of patients with dose limiting toxiciti...   \n",
              "39  Number of Participants Who Experienced Dose-Li...   \n",
              "40  Solid Tumor Growth After Completion of Interve...   \n",
              "41                              Overall Survival (OS)   \n",
              "42  Find Etoposide Drug Targets' SNP Genotypes whi...   \n",
              "43                        Pharmacokinetic interaction   \n",
              "44                              Overall Response Rate   \n",
              "45  Change from baseline (i.e. first chemotherapy ...   \n",
              "46                            Objective response rate   \n",
              "47               Six-months progression-free survival   \n",
              "48  Assess the safety and tolerability of Cedirani...   \n",
              "49         Progression-Free-Survival rate at 6 months   \n",
              "50  Number of Participants With Bone Bio-marker Re...   \n",
              "51  Phase 1 Only: Safety and Tolerability of INCB0...   \n",
              "52  search for EGFR, KRAS, BRAF, PIK3CA, HER2, ERB...   \n",
              "53  Number of participants with dose limiting toxi...   \n",
              "54  Change in tumor perfusion as based on Dynamic ...   \n",
              "55                              Overall survival (OS)   \n",
              "56           Determine the Overall Objective Response   \n",
              "57  The Safety and Toxicity of ALT-801 in Patients...   \n",
              "58  Phase 1a: To determine the recommended phase 2...   \n",
              "59                    Progression-Free Survival (PFS)   \n",
              "\n",
              "                                   Secondary_Measures  \\\n",
              "0                                                 NaN   \n",
              "1   Objective response rate | Duration of response...   \n",
              "2   Incidence of Adverse Events (AE) and Dose-Limi...   \n",
              "3                                                 NaN   \n",
              "4                                              safety   \n",
              "5                                                 NaN   \n",
              "6   Phase 1: Best Overall Response | Phase 2: Comp...   \n",
              "7        Progression Free Survival | Overall Survival   \n",
              "8   Area under the concentration curve (AUC) of NP...   \n",
              "9                                      Immunogenicity   \n",
              "10  Overall Response Rate (ORR) | Best Overall Res...   \n",
              "11  ORR (Objective Response Rate) | PFS (Progressi...   \n",
              "12  Diagnostic sensitivity | Diagnostic yield (str...   \n",
              "13  Frequency of Adverse Events: Number of Partici...   \n",
              "14  Progression-free Survival | Overall Survival |...   \n",
              "15  Overall Response Rate (ORR) | Disease Control ...   \n",
              "16  To determine objective response (CR+PR), time ...   \n",
              "17  PFS | Number of participants with treatment-re...   \n",
              "18  ventricular function evaluation. | serum tropo...   \n",
              "19  Change in Quality of Life (QOL) From Baseline ...   \n",
              "20  Objective Response Rate (ORR) | Duration of Re...   \n",
              "21                                                NaN   \n",
              "22  Number of Participants With Overall Survival a...   \n",
              "23  ORR | intracranial objective response rate (iO...   \n",
              "24                                                NaN   \n",
              "25           Overall Survival | Overall response rate   \n",
              "26                                                NaN   \n",
              "27  Patient knowledge of the goals of care assesse...   \n",
              "28  Objective Response Rate (ORR) | Duration Of Re...   \n",
              "29  Percent of Patients with best response as eith...   \n",
              "30  Treatment toxicities | Progression-free surviv...   \n",
              "31  Cmax | Tmax | t1/2 | AUC0-t | the objective re...   \n",
              "32  Progression-free survival | Complete metabolic...   \n",
              "33  Safety parameters in terms of AE, laboratory a...   \n",
              "34  Phase 1: Objective Response Rate (ORR) as Dete...   \n",
              "35  To assess the frequency of grade I, II and III...   \n",
              "36  Objective Response Rate | Overall Survival (OS...   \n",
              "37  Part 1 Arm B: Average concentration of ipilimu...   \n",
              "38  Overall response rate (ORR) | Disease control ...   \n",
              "39  Confirmed Objective Response Rate (ORR) | Best...   \n",
              "40       Progression-free Survival | Overall Survival   \n",
              "41  Progression-Free Survival (PFS) | Objective Re...   \n",
              "42                                                NaN   \n",
              "43                                                NaN   \n",
              "44  Overall Survival | Progression Free Survival |...   \n",
              "45  Change from baseline (i.e. first chemotherapy ...   \n",
              "46  Progression-free survival | Time tumor progres...   \n",
              "47                Survival | Response rate | Toxicity   \n",
              "48  Preliminary efficacy assessment of Cediranib i...   \n",
              "49                                   ORR | mPFS | mOS   \n",
              "50  Number of Patients With Skeletal-related Event...   \n",
              "51  Phase 2 Only: Safety and Tolerability of INCB0...   \n",
              "52  comparison of genome profiles (mutations and r...   \n",
              "53  Number of participants with treatment-emergent...   \n",
              "54  Changes in response rate using Response evalua...   \n",
              "55                                                OS1   \n",
              "56                                                NaN   \n",
              "57  Clinical Antitumor Response to ALT-801 | ALT-8...   \n",
              "58  To characterize the pharmacokinetics (PK) prop...   \n",
              "59  Overall Survival (OS) | Objective Response Rat...   \n",
              "\n",
              "                                        Interventions elig_len  \\\n",
              "0                                    DRUG:fenretinide     1815   \n",
              "1   OTHER:DPX-Survivac | DRUG:Cyclophosphamide | D...     2335   \n",
              "2                                         DRUG:CS1001     1904   \n",
              "3   OTHER:Characterise the molecular epidemiology ...      535   \n",
              "4   RADIATION:Radiation Prophylactic Cranial Irrad...      741   \n",
              "5        OTHER:Preventive Multimedia Teaching Program      469   \n",
              "6   DRUG:pemetrexed | DRUG:cisplatin | RADIATION:r...      677   \n",
              "7                                    DRUG:becatecarin     1534   \n",
              "8                                         DRUG:NPX267     1146   \n",
              "9                                 BIOLOGICAL:IDC-G305     1622   \n",
              "10  DRUG:LY4066434. | DRUG:Cetuximab | DRUG:Nab pa...     1600   \n",
              "11  BEHAVIORAL:Symptom cluster-based care interven...      321   \n",
              "12  DEVICE:Neelde Based Confocal Laser Endomicrosc...     1362   \n",
              "13  DRUG:Viagenpumatucel-L | DRUG:Metronomic Cyclo...     1320   \n",
              "14  DRUG:pemetrexed | DRUG:carboplatin | PROCEDURE...      531   \n",
              "15  DRUG:HS-10370 | DRUG:HS-20117 | DRUG:Adebrelim...     1965   \n",
              "16                                     DRUG:erlotinib     2779   \n",
              "17  DRUG:Temozolomide | DRUG:first-line chemothera...     2052   \n",
              "18  DRUG:Nivolumab | DEVICE:MRI | BIOLOGICAL:BLOOD...      520   \n",
              "19                        OTHER:Early palliative care     1416   \n",
              "20                                   DRUG:PF-08046876      853   \n",
              "21                                     DRUG:[F 18]HX4     2182   \n",
              "22  DRUG:Pembrolizumab | DRUG:Nab paclitaxel | DRU...     1413   \n",
              "23  DRUG:Gefitinib and Pemetrexed/platinum | DRUG:...     2493   \n",
              "24                         DRUG:NS-9 [Poly I: Poly C]     2344   \n",
              "25  COMBINATION_PRODUCT:RRx-001 + eLOOP Device | D...     1831   \n",
              "26                DRUG:OSI-211 (Liposomal Lurtotecan)      623   \n",
              "27  BEHAVIORAL:Truthful information on chemotherap...      432   \n",
              "28  DRUG:Tislelizumab, Carboplatin /Cisplatin, Eto...     1433   \n",
              "29                             BIOLOGICAL:TCR-T cells     1102   \n",
              "30  DRUG:irinotecan plus lobaplatin | DRUG:irinotecan     1107   \n",
              "31                                    DRUG:BPI-442096     1902   \n",
              "32  OTHER:First line systemic treatment | OTHER:Ra...     1360   \n",
              "33  BIOLOGICAL:chemotherapy followed dendritic cel...     2870   \n",
              "34                    DRUG:MEDI4736 | DRUG:INCB024360     1461   \n",
              "35                                     DRUG:Diprosone      598   \n",
              "36            BIOLOGICAL:Neoantigen loaded DC vaccine     1077   \n",
              "37  DRUG:ipilimumab | DRUG:nivolumab | DRUG:ENHANZ...     1406   \n",
              "38              DRUG:225Ac-ETN029 | DRUG:111In-ETN029     2351   \n",
              "39  COMBINATION_PRODUCT:TTX-030, budigalimab and m...      820   \n",
              "40                                     DRUG:Cisplatin      621   \n",
              "41  DRUG:Ceralasertib | DRUG:Durvalumab | DRUG:Doc...     2348   \n",
              "42    DRUG:ETOPOSIDE - Usual | DRUG:ETOPOSIDE - Study     1499   \n",
              "43  DRUG:Rapamycin (sirolimus) | OTHER:Grapefruit ...     2933   \n",
              "44                   DRUG:pemetrexed | DRUG:cisplatin     2010   \n",
              "45                         OTHER:Nursing Intervention      531   \n",
              "46  BIOLOGICAL:Activated CIK and CD3-MUC1 Bispecif...     2631   \n",
              "47  DRUG:Adriamycin, cyclophosphamide, vindesine, ...     1962   \n",
              "48     DRUG:AZD2171 | DRUG:Etoposide | DRUG:Cisplatin      606   \n",
              "49             DRUG:Liposomal Irinotecan and Apatinib      798   \n",
              "50                                  DRUG:Cabozantinib     1096   \n",
              "51  DRUG:INCB001158 | DRUG:Epacadostat | DRUG:Pemb...     2036   \n",
              "52                         OTHER:blood sample, biopsy      746   \n",
              "53  DRUG:PF-07799544 | DRUG:PF-07799933 | DRUG:enc...      986   \n",
              "54                                    DRUG:177Lu-J591     3265   \n",
              "55              DRUG:MGN1703 | OTHER:Standard of care     1492   \n",
              "56                                     DRUG:dasatinib     2450   \n",
              "57                                 BIOLOGICAL:ALT-801     2425   \n",
              "58  DRUG:LY4170156 | DRUG:bevacizumab | DRUG:carbo...     1251   \n",
              "59  DRUG:Organoid Drug Sensitivity Testing-Guided ...     2304   \n",
              "\n",
              "                                     eligibility_json  \n",
              "0   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "1   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "2   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "3   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "4   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "5   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "6   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "7   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "8   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "9   {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "10  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "11  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "12  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "13  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "14  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "15  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "16  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "17  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "18  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "19  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "20  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "21  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "22  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "23  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "24  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "25  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "26  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "27  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "28  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "29  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "30  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "31  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "32  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "33  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "34  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "35  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "36  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "37  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "38  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "39  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "40  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "41  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "42  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "43  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "44  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "45  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "46  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "47  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "48  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "49  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "50  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "51  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "52  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "53  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "54  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "55  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "56  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "57  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "58  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "59  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "\n",
              "[60 rows x 21 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-ed1effe5-8ba8-41a7-a6a0-afe51fe71738\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>NCT_ID</th>\n",
              "      <th>Title</th>\n",
              "      <th>Official_Title</th>\n",
              "      <th>Status</th>\n",
              "      <th>Start_Date</th>\n",
              "      <th>Primary_Completion</th>\n",
              "      <th>Study_Type</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>...</th>\n",
              "      <th>Min_Age</th>\n",
              "      <th>Max_Age</th>\n",
              "      <th>Lead_Sponsor</th>\n",
              "      <th>Brief_Summary</th>\n",
              "      <th>Eligibility</th>\n",
              "      <th>Primary_Measures</th>\n",
              "      <th>Secondary_Measures</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>elig_len</th>\n",
              "      <th>eligibility_json</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>NCT00009971</td>\n",
              "      <td>Fenretinide in Treating Patients With Recurren...</td>\n",
              "      <td>Phase II Trial Of Fenretinide (NSC-374551; IND...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2000-11</td>\n",
              "      <td>2005-09</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>32</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>National Cancer Institute (NCI)</td>\n",
              "      <td>Phase II trial to study the effectiveness of f...</td>\n",
              "      <td>DISEASE CHARACTERISTICS: * Histologically or c...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DRUG:fenretinide</td>\n",
              "      <td>1815</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>NCT03836352</td>\n",
              "      <td>Study of an Immunotherapeutic, DPX-Survivac, i...</td>\n",
              "      <td>A Phase 2, Open-label, Multicenter, Study of a...</td>\n",
              "      <td>ACTIVE_NOT_RECRUITING</td>\n",
              "      <td>2018-12-21</td>\n",
              "      <td>2023-12-31</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>184</td>\n",
              "      <td>Ovarian Cancer, Hepatocellular Carcinoma, Non-...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ImmunoVaccine Technologies, Inc. (IMV Inc.)</td>\n",
              "      <td>This study will assess the safety and efficacy...</td>\n",
              "      <td>Key Inclusion Criteria: * Subjects with advanc...</td>\n",
              "      <td>Efficacy as measured by objective response rat...</td>\n",
              "      <td>Objective response rate | Duration of response...</td>\n",
              "      <td>OTHER:DPX-Survivac | DRUG:Cyclophosphamide | D...</td>\n",
              "      <td>2335</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NCT04421352</td>\n",
              "      <td>Safety and Tolerability Evaluation of Low-dose...</td>\n",
              "      <td>A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2021-01-12</td>\n",
              "      <td>2023-12-22</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>11</td>\n",
              "      <td>Relapsed Small Cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>75 Years</td>\n",
              "      <td>CStone Pharmaceuticals</td>\n",
              "      <td>A Phase Ia/Ib Safety and Tolerability Evaluati...</td>\n",
              "      <td>Inclusion Criteria: 1. Patients with histologi...</td>\n",
              "      <td>To determine the recommended radiation dose an...</td>\n",
              "      <td>Incidence of Adverse Events (AE) and Dose-Limi...</td>\n",
              "      <td>DRUG:CS1001</td>\n",
              "      <td>1904</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>NCT01774526</td>\n",
              "      <td>Molecular Epidemiology of Lung Adenocarcinoma ...</td>\n",
              "      <td>Molecular Epidemiology of Lung Adenocarcinoma ...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2010-12</td>\n",
              "      <td>2016-12</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NaN</td>\n",
              "      <td>40</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>21 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>National University Hospital, Singapore</td>\n",
              "      <td>Lung Cancer continues to be the major cause of...</td>\n",
              "      <td>Inclusion Criteria: * Asian ethnicity * Age \\&gt;...</td>\n",
              "      <td>Descriptive study of our patients with lung ad...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>OTHER:Characterise the molecular epidemiology ...</td>\n",
              "      <td>535</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>NCT01780675</td>\n",
              "      <td>Hippocampus Avoidance PCI vs PCI</td>\n",
              "      <td>Prophylactic Cranial Irradiation With or Witho...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2013-04</td>\n",
              "      <td>2019-04-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE3</td>\n",
              "      <td>168</td>\n",
              "      <td>Small Cell Lung Cancer, Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>The Netherlands Cancer Institute</td>\n",
              "      <td>Using Intensity Modulated radiotherapy it is p...</td>\n",
              "      <td>Inclusion Criteria: * \\- Small Cell Lung Cance...</td>\n",
              "      <td>neurocognitive decline</td>\n",
              "      <td>safety</td>\n",
              "      <td>RADIATION:Radiation Prophylactic Cranial Irrad...</td>\n",
              "      <td>741</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>NCT03231111</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2017-07-25</td>\n",
              "      <td>2018-07-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NaN</td>\n",
              "      <td>60</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>20 Years</td>\n",
              "      <td>80 Years</td>\n",
              "      <td>National Taiwan University Hospital</td>\n",
              "      <td>The Effectiveness of Using Preventive Multimed...</td>\n",
              "      <td>Inclusion Criteria: 1. Patients older than 20 ...</td>\n",
              "      <td>skindex-29</td>\n",
              "      <td>NaN</td>\n",
              "      <td>OTHER:Preventive Multimedia Teaching Program</td>\n",
              "      <td>469</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>NCT00447421</td>\n",
              "      <td>A Study to Treat Small Cell Lung Cancer With a...</td>\n",
              "      <td>Phase I/II Study of Concurrent Cisplatin, Peme...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2007-02</td>\n",
              "      <td>2008-05</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1, PHASE2</td>\n",
              "      <td>9</td>\n",
              "      <td>Small Cell Lung Cancer, Carcinoma, Small Cell,...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Eli Lilly and Company</td>\n",
              "      <td>The purpose of this study is to determine the ...</td>\n",
              "      <td>Inclusion Criteria: * Measurable disease with ...</td>\n",
              "      <td>Phase 1: Maximum Tolerated Dose | Phase 2: Ove...</td>\n",
              "      <td>Phase 1: Best Overall Response | Phase 2: Comp...</td>\n",
              "      <td>DRUG:pemetrexed | DRUG:cisplatin | RADIATION:r...</td>\n",
              "      <td>677</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>NCT00084487</td>\n",
              "      <td>Rebeccamycin Analog as Second-Line Therapy in ...</td>\n",
              "      <td>Phase II Trial of XL119 (Rebeccamycin Analogue...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2004-04</td>\n",
              "      <td>2008-04</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>21</td>\n",
              "      <td>Extensive Stage Small Cell Lung Cancer, Limite...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>National Cancer Institute (NCI)</td>\n",
              "      <td>Drugs used in chemotherapy, such as rebeccamyc...</td>\n",
              "      <td>Inclusion Criteria: * Diagnosis of small cell ...</td>\n",
              "      <td>Objective Response Rate Estimated as the Propo...</td>\n",
              "      <td>Progression Free Survival | Overall Survival</td>\n",
              "      <td>DRUG:becatecarin</td>\n",
              "      <td>1534</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>NCT05958199</td>\n",
              "      <td>A Study of NPX267 for Subjects With Solid Tumo...</td>\n",
              "      <td>A Phase 1a/1b, Dose-Escalation/Dose-Expansion ...</td>\n",
              "      <td>SUSPENDED</td>\n",
              "      <td>2023-07-21</td>\n",
              "      <td>2025-09-20</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>131</td>\n",
              "      <td>Metastatic Malignant Neoplasm</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NextPoint Therapeutics, Inc.</td>\n",
              "      <td>NPX267 is an antibody drug targeting the inhib...</td>\n",
              "      <td>Inclusion Criteria: * Histologically or cytolo...</td>\n",
              "      <td>Incidence of dose limiting toxicity | Incidenc...</td>\n",
              "      <td>Area under the concentration curve (AUC) of NP...</td>\n",
              "      <td>DRUG:NPX267</td>\n",
              "      <td>1146</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>NCT02015416</td>\n",
              "      <td>A Phase 1 Trial of NY-ESO-1 With GLA-SE in Pat...</td>\n",
              "      <td>A Phase 1 Open Label, Multicenter, Multiple As...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2013-11</td>\n",
              "      <td>2016-12</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>13</td>\n",
              "      <td>Melanoma, Ovarian Cancer, Sarcoma, Non-small C...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>80 Years</td>\n",
              "      <td>Immune Design, a subsidiary of Merck &amp; Co., In...</td>\n",
              "      <td>This is a Phase I, multi-center, multiple asce...</td>\n",
              "      <td>Inclusion Criteria: * Confirmed diagnosis of m...</td>\n",
              "      <td>Safety and tolerability</td>\n",
              "      <td>Immunogenicity</td>\n",
              "      <td>BIOLOGICAL:IDC-G305</td>\n",
              "      <td>1622</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>NCT06607185</td>\n",
              "      <td>A Study of the Pan-KRAS Inhibitor LY4066434 in...</td>\n",
              "      <td>A Phase 1a/1b Study of the Pan-KRAS Inhibitor ...</td>\n",
              "      <td>RECRUITING</td>\n",
              "      <td>2024-10-21</td>\n",
              "      <td>2030-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>750</td>\n",
              "      <td>Pancreatic Ductal Adenocarcinoma, Non-small Ce...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Eli Lilly and Company</td>\n",
              "      <td>The main purpose of the study is to assess whe...</td>\n",
              "      <td>Inclusion Criteria: * Have evidence of KRAS G1...</td>\n",
              "      <td>Number of Participants with Dose-limiting Toxi...</td>\n",
              "      <td>Overall Response Rate (ORR) | Best Overall Res...</td>\n",
              "      <td>DRUG:LY4066434. | DRUG:Cetuximab | DRUG:Nab pa...</td>\n",
              "      <td>1600</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>NCT06725225</td>\n",
              "      <td>Machine Learning for Predicting and Managing Q...</td>\n",
              "      <td>Development of a Machine Learning-Based Risk P...</td>\n",
              "      <td>NOT_YET_RECRUITING</td>\n",
              "      <td>2025-01-01</td>\n",
              "      <td>2025-12-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NaN</td>\n",
              "      <td>200</td>\n",
              "      <td>Lung Cancer Patients</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Second Affiliated Hospital of Zunyi Medical Un...</td>\n",
              "      <td>The goal of this study is to explore whether h...</td>\n",
              "      <td>Inclusion Criteria: 1. Histologically diagnose...</td>\n",
              "      <td>EORTC QLQ C30 | EORTC QLQ LC-13</td>\n",
              "      <td>ORR (Objective Response Rate) | PFS (Progressi...</td>\n",
              "      <td>BEHAVIORAL:Symptom cluster-based care interven...</td>\n",
              "      <td>321</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>NCT06079970</td>\n",
              "      <td>Confocal Laser Endomicroscopy VERification</td>\n",
              "      <td>Bronchoscopy With and Without Needle-based Con...</td>\n",
              "      <td>RECRUITING</td>\n",
              "      <td>2023-10-18</td>\n",
              "      <td>2025-10-18</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NaN</td>\n",
              "      <td>208</td>\n",
              "      <td>Lung Cancer, Lung Neoplasm Malignant, Carcinom...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Amsterdam University Medical Centers (UMC), Lo...</td>\n",
              "      <td>The goal of this multi-center randomized clini...</td>\n",
              "      <td>Inclusion Criteria: 1. â‰¥18 years of age 2. Sus...</td>\n",
              "      <td>Diagnostic yield (intermediate definition)</td>\n",
              "      <td>Diagnostic sensitivity | Diagnostic yield (str...</td>\n",
              "      <td>DEVICE:Neelde Based Confocal Laser Endomicrosc...</td>\n",
              "      <td>1362</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>NCT02117024</td>\n",
              "      <td>A Phase 2 Study of Viagenpumatucel-L (HS-110) ...</td>\n",
              "      <td>A Phase 2, Multicenter, Randomized Study to Ev...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2014-07</td>\n",
              "      <td>2017-12</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>66</td>\n",
              "      <td>Non Small Cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Heat Biologics</td>\n",
              "      <td>Determine whether viagenpumatucel-L combined w...</td>\n",
              "      <td>Inclusion Criteria: * Non-small cell lung aden...</td>\n",
              "      <td>Overall Survival (OS)</td>\n",
              "      <td>Frequency of Adverse Events: Number of Partici...</td>\n",
              "      <td>DRUG:Viagenpumatucel-L | DRUG:Metronomic Cyclo...</td>\n",
              "      <td>1320</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>NCT00494026</td>\n",
              "      <td>Chemotherapy and Radiotherapy to Treat Patient...</td>\n",
              "      <td>Phase II Study of Concurrent Carboplatin, Peme...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2007-09</td>\n",
              "      <td>2008-10</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>4</td>\n",
              "      <td>Small Cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Eli Lilly and Company</td>\n",
              "      <td>This is a multicenter, phase II, open-label tr...</td>\n",
              "      <td>Inclusion Criteria: * Histologic and/or cytolo...</td>\n",
              "      <td>Proportion of Patients With a Complete or Part...</td>\n",
              "      <td>Progression-free Survival | Overall Survival |...</td>\n",
              "      <td>DRUG:pemetrexed | DRUG:carboplatin | PROCEDURE...</td>\n",
              "      <td>531</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>NCT06963502</td>\n",
              "      <td>A Phase Ib Study of HS-10370 in Addition to Ot...</td>\n",
              "      <td>A Phase Ib Study Evaluating the Safety, Tolera...</td>\n",
              "      <td>NOT_YET_RECRUITING</td>\n",
              "      <td>2025-05-30</td>\n",
              "      <td>2028-12-31</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>762</td>\n",
              "      <td>Advanced Solid Tumors, Colorectal Cancer, Non-...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Jiangsu Hansoh Pharmaceutical Co., Ltd.</td>\n",
              "      <td>This is a Phase Ib study that will evaluate th...</td>\n",
              "      <td>Inclusion Criteria: * Men or women greater tha...</td>\n",
              "      <td>Number of Participants with Adverse Event(s) (...</td>\n",
              "      <td>Overall Response Rate (ORR) | Disease Control ...</td>\n",
              "      <td>DRUG:HS-10370 | DRUG:HS-20117 | DRUG:Adebrelim...</td>\n",
              "      <td>1965</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>NCT00663689</td>\n",
              "      <td>Efficacy of Erlotinib for Brain Metastasis of ...</td>\n",
              "      <td>A Phase II Study of Erlotinib in Benefitted Pa...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2008-03</td>\n",
              "      <td>2011-03</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>45</td>\n",
              "      <td>Non-Small Cell Lung Cancer, Brain Metastases</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Guangdong Provincial People's Hospital</td>\n",
              "      <td>This is a non-randomized open-label uncontroll...</td>\n",
              "      <td>Inclusion criteria: 1. Histological or cytolog...</td>\n",
              "      <td>Time of asymptomatic brain metastasis turn int...</td>\n",
              "      <td>To determine objective response (CR+PR), time ...</td>\n",
              "      <td>DRUG:erlotinib</td>\n",
              "      <td>2779</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>NCT02772107</td>\n",
              "      <td>Temozolomide as Maintenance Therapy Following ...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2015-12</td>\n",
              "      <td>2017-06</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2, PHASE3</td>\n",
              "      <td>132</td>\n",
              "      <td>Extensive-stage Small Cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>75 Years</td>\n",
              "      <td>Chinese PLA General Hospital</td>\n",
              "      <td>Temozolomide may delay progression in sequence...</td>\n",
              "      <td>Inclusion Criteria: * Cytologically and/or his...</td>\n",
              "      <td>PFS of the maintenance therapy</td>\n",
              "      <td>PFS | Number of participants with treatment-re...</td>\n",
              "      <td>DRUG:Temozolomide | DRUG:first-line chemothera...</td>\n",
              "      <td>2052</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>NCT03313544</td>\n",
              "      <td>Evolution of the Heart Function When Monitorin...</td>\n",
              "      <td>Evolution of the Heart Function When Monitorin...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2018-04-09</td>\n",
              "      <td>2024-10</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE4</td>\n",
              "      <td>50</td>\n",
              "      <td>Melanoma, Non-small Cell, Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Assistance Publique Hopitaux De Marseille</td>\n",
              "      <td>Prospective, monocentric clinical study. Patie...</td>\n",
              "      <td>Inclusion Criteria: patients treated with nivo...</td>\n",
              "      <td>systolic pulmonary arterial pressure</td>\n",
              "      <td>ventricular function evaluation. | serum tropo...</td>\n",
              "      <td>DRUG:Nivolumab | DEVICE:MRI | BIOLOGICAL:BLOOD...</td>\n",
              "      <td>520</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>NCT02349412</td>\n",
              "      <td>Early Palliative Care With Standard Care or St...</td>\n",
              "      <td>Randomized Study of Early Palliative Care Inte...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2015-06-25</td>\n",
              "      <td>2017-07-03</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE3</td>\n",
              "      <td>405</td>\n",
              "      <td>Liver Cancer, Anxiety Disorder, Depression, Sm...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Alliance for Clinical Trials in Oncology</td>\n",
              "      <td>The study intervention consists of the early i...</td>\n",
              "      <td>Study Patient Participant Eligibility Requirem...</td>\n",
              "      <td>Change in Quality of Life (QOL) From Baseline ...</td>\n",
              "      <td>Change in Quality of Life (QOL) From Baseline ...</td>\n",
              "      <td>OTHER:Early palliative care</td>\n",
              "      <td>1416</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>NCT07090499</td>\n",
              "      <td>A Study to Learn About the Study Medicine Call...</td>\n",
              "      <td>A Phase 1 Open-label Study to Investigate PF-0...</td>\n",
              "      <td>RECRUITING</td>\n",
              "      <td>2025-08-20</td>\n",
              "      <td>2028-07-08</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>310</td>\n",
              "      <td>Advanced/Metastatic Solid Tumors, Bladder Canc...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Pfizer</td>\n",
              "      <td>The purpose of the study is to explore the saf...</td>\n",
              "      <td>Inclusion Criteria: * 18 years of age or older...</td>\n",
              "      <td>Incidence of Treatment Emergent Adverse Events...</td>\n",
              "      <td>Objective Response Rate (ORR) | Duration of Re...</td>\n",
              "      <td>DRUG:PF-08046876</td>\n",
              "      <td>853</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>NCT01075399</td>\n",
              "      <td>Study of [F 18]HX4 Positron Emission Tomograph...</td>\n",
              "      <td>A Pilot, Phase II , Open Label, Nonrandomized,...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2010-02</td>\n",
              "      <td>2011-05</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>50</td>\n",
              "      <td>Head and Neck Cancer, Lung Cancer, Liver Cance...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Siemens Molecular Imaging</td>\n",
              "      <td>This pilot phase II study is designed as a tes...</td>\n",
              "      <td>Inclusion Criteria: * Patient is \\&gt;18 years an...</td>\n",
              "      <td>Reproducibility of [F18]HX4 PET Imaging in Mea...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DRUG:[F 18]HX4</td>\n",
              "      <td>2182</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>NCT04964960</td>\n",
              "      <td>Pembro+Chemo in Brain Mets</td>\n",
              "      <td>Phase II Investigation of Use of CNS Active Pe...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2022-05-19</td>\n",
              "      <td>2023-06-19</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>3</td>\n",
              "      <td>Lung Cancer, Lung Cancer Metastatic, Brain Can...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>85 Years</td>\n",
              "      <td>John L. Villano, MD, PhD</td>\n",
              "      <td>The goal of this study is to evaluate whether ...</td>\n",
              "      <td>Inclusion Criteria: * Non-small cell lunch can...</td>\n",
              "      <td>Disease Control Rate</td>\n",
              "      <td>Number of Participants With Overall Survival a...</td>\n",
              "      <td>DRUG:Pembrolizumab | DRUG:Nab paclitaxel | DRU...</td>\n",
              "      <td>1413</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>NCT01951469</td>\n",
              "      <td>Gefitinib With or Without Chemotherapy in Brai...</td>\n",
              "      <td>Multicenter Phase III Study of Gefitinib Mono-...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2016-01</td>\n",
              "      <td>2022-06</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE3</td>\n",
              "      <td>160</td>\n",
              "      <td>Non-small Cell Lung Cancer, Brain Metastases, ...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>75 Years</td>\n",
              "      <td>Sun Yat-sen University</td>\n",
              "      <td>This is a multi-center phase III randomized co...</td>\n",
              "      <td>Inclusion Criteria: 1. Patient who was confirm...</td>\n",
              "      <td>iPFS(intracranial progression free survival</td>\n",
              "      <td>ORR | intracranial objective response rate (iO...</td>\n",
              "      <td>DRUG:Gefitinib and Pemetrexed/platinum | DRUG:...</td>\n",
              "      <td>2493</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>NCT00094003</td>\n",
              "      <td>Study of NS-9 in Patients With Liver Metastases</td>\n",
              "      <td>A Phase I, Open-Label, Dose Escalation Study o...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2002-09</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>20</td>\n",
              "      <td>Liver Neoplasms, Neoplasm Metastasis, Local Ne...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NS Pharma, Inc.</td>\n",
              "      <td>This study is to investigate the safety of NS-...</td>\n",
              "      <td>Inclusion Criteria: * Male and female at least...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DRUG:NS-9 [Poly I: Poly C]</td>\n",
              "      <td>2344</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>NCT03699956</td>\n",
              "      <td>RRx-001 Sequentially With a Platinum Doublet o...</td>\n",
              "      <td>A Phase 3, Controlled, Open-label, Randomized ...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2018-12-24</td>\n",
              "      <td>2022-08-11</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE3</td>\n",
              "      <td>18</td>\n",
              "      <td>Carcinoma, Small Cell Lung</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>79 Years</td>\n",
              "      <td>EpicentRx, Inc.</td>\n",
              "      <td>This Phase 3 study aims to find out whether RR...</td>\n",
              "      <td>Inclusion Criteria: 1. Age â‰¥ 18 and \\&lt; 80 year...</td>\n",
              "      <td>Progression Free Survival</td>\n",
              "      <td>Overall Survival | Overall response rate</td>\n",
              "      <td>COMBINATION_PRODUCT:RRx-001 + eLOOP Device | D...</td>\n",
              "      <td>1831</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>NCT00046787</td>\n",
              "      <td>Efficacy and Safety Study of OSI-211 (Liposoma...</td>\n",
              "      <td>Phase II Study to Determine the Efficacy of OS...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2002-09</td>\n",
              "      <td>NaN</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>47</td>\n",
              "      <td>SCLC, Carcinoma, Small Cell</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Astellas Pharma Inc</td>\n",
              "      <td>The purpose of this study is to determine whet...</td>\n",
              "      <td>Inclusion Criteria: * Confirmed recurrent smal...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DRUG:OSI-211 (Liposomal Lurtotecan)</td>\n",
              "      <td>623</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>27</th>\n",
              "      <td>NCT02606149</td>\n",
              "      <td>Truthful Information on Chemotherapy and Its I...</td>\n",
              "      <td>Impact of a Truthful Information Concerning Ch...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2016-07-15</td>\n",
              "      <td>2020-10-15</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NaN</td>\n",
              "      <td>123</td>\n",
              "      <td>Stage IV Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Assistance Publique - HÃ´pitaux de Paris</td>\n",
              "      <td>Patients with metastatic cancer have a substan...</td>\n",
              "      <td>Inclusion Criteria: * stage IV lung cancer, hi...</td>\n",
              "      <td>Number of patients receiving chemotherapy in t...</td>\n",
              "      <td>Patient knowledge of the goals of care assesse...</td>\n",
              "      <td>BEHAVIORAL:Truthful information on chemotherap...</td>\n",
              "      <td>432</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>28</th>\n",
              "      <td>NCT06838208</td>\n",
              "      <td>Tislelizumab Combined With Chemotherapy and Re...</td>\n",
              "      <td>Efficacy and Safety of Tislelizumab Combined W...</td>\n",
              "      <td>RECRUITING</td>\n",
              "      <td>2025-02-25</td>\n",
              "      <td>2027-03-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>56</td>\n",
              "      <td>Extensive-stage Small Cell Lung Cancer (ES-SCLC)</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Anhui Provincial Cancer Hospital</td>\n",
              "      <td>To explore the efficacy and safety of Tisleliz...</td>\n",
              "      <td>Inclusion Criteria: 1. Ageâ‰¥18 years old, male ...</td>\n",
              "      <td>Progression Free Survival (PFS)</td>\n",
              "      <td>Objective Response Rate (ORR) | Duration Of Re...</td>\n",
              "      <td>DRUG:Tislelizumab, Carboplatin /Cisplatin, Eto...</td>\n",
              "      <td>1433</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>29</th>\n",
              "      <td>NCT03778814</td>\n",
              "      <td>TCR-T Cell Immunotherapy of Lung Cancer and Ot...</td>\n",
              "      <td>TCR-T Cells Targeting Cancer Cells for Immunot...</td>\n",
              "      <td>RECRUITING</td>\n",
              "      <td>2018-12-01</td>\n",
              "      <td>2029-12-30</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>30</td>\n",
              "      <td>Nonsmall Cell Lung Cancer, Solid Tumor, Adult</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>75 Years</td>\n",
              "      <td>Second Affiliated Hospital of Guangzhou Medica...</td>\n",
              "      <td>Tumor organoids and TILs (and/or peripheral T ...</td>\n",
              "      <td>Inclusion Criteria: 1. patients with advanced ...</td>\n",
              "      <td>Number of Patients with Dose Limiting Toxicity</td>\n",
              "      <td>Percent of Patients with best response as eith...</td>\n",
              "      <td>BIOLOGICAL:TCR-T cells</td>\n",
              "      <td>1102</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>NCT03613753</td>\n",
              "      <td>Irinotecan Plus Lobaplatin Versus Irinotecan i...</td>\n",
              "      <td>A Randomized Phase II Trial of Irinotecan Plus...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2018-06-01</td>\n",
              "      <td>2020-06-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>72</td>\n",
              "      <td>Small-cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>70 Years</td>\n",
              "      <td>ShengFa Su</td>\n",
              "      <td>This randomized phase II study compare surviva...</td>\n",
              "      <td>Inclusion Criteria: * Relapsed SCLC * Etoposid...</td>\n",
              "      <td>Objective Response Rate (ORR)</td>\n",
              "      <td>Treatment toxicities | Progression-free surviv...</td>\n",
              "      <td>DRUG:irinotecan plus lobaplatin | DRUG:irinotecan</td>\n",
              "      <td>1107</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>31</th>\n",
              "      <td>NCT05369312</td>\n",
              "      <td>Phase 1 Study of BPI-442096 in Advanced Solid ...</td>\n",
              "      <td>Phase 1 Study of BPI-442096 in Advanced Solid ...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2022-06</td>\n",
              "      <td>2024-05-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>230</td>\n",
              "      <td>Solid Tumor, Non-small Cell Lung Cancer, Pancr...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>75 Years</td>\n",
              "      <td>Betta Pharmaceuticals Co., Ltd.</td>\n",
              "      <td>A first-in-human study to evaluate the safety,...</td>\n",
              "      <td>Inclusion Criteria: * Signed informed consent;...</td>\n",
              "      <td>The adverse events (AEs) | Determine the recom...</td>\n",
              "      <td>Cmax | Tmax | t1/2 | AUC0-t | the objective re...</td>\n",
              "      <td>DRUG:BPI-442096</td>\n",
              "      <td>1902</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>NCT02805530</td>\n",
              "      <td>Radical Treatment of Synchronous Oligometastat...</td>\n",
              "      <td>Radical Treatment of Synchronous Oligometastat...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2015-06</td>\n",
              "      <td>2018-08</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NaN</td>\n",
              "      <td>36</td>\n",
              "      <td>Carcinoma, Non-Small-Cell Lung, Synchronous Ne...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Instituto Nacional de Cancerologia de Mexico</td>\n",
              "      <td>Non-small cell lung cancer (NSCLC) is the most...</td>\n",
              "      <td>Inclusion Criteria: * Pathology diagnosis of n...</td>\n",
              "      <td>Overall survival</td>\n",
              "      <td>Progression-free survival | Complete metabolic...</td>\n",
              "      <td>OTHER:First line systemic treatment | OTHER:Ra...</td>\n",
              "      <td>1360</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>33</th>\n",
              "      <td>NCT02669719</td>\n",
              "      <td>Cellular Immunotherapy Synergize Chemotherapy ...</td>\n",
              "      <td>A Randomized Phase II Study to Evaluate Effica...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2016-01</td>\n",
              "      <td>2017-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>70</td>\n",
              "      <td>Non Small Cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Shanghai Chest Hospital</td>\n",
              "      <td>This is a randomized, open-label, phaseâ…¡ study...</td>\n",
              "      <td>Inclusion Criteria: 1. Histologically or cytol...</td>\n",
              "      <td>Progression-free survival</td>\n",
              "      <td>Safety parameters in terms of AE, laboratory a...</td>\n",
              "      <td>BIOLOGICAL:chemotherapy followed dendritic cel...</td>\n",
              "      <td>2870</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>34</th>\n",
              "      <td>NCT02318277</td>\n",
              "      <td>A Study of Epacadostat (INCB024360) in Combina...</td>\n",
              "      <td>A Phase 1/2 Study Exploring the Safety, Tolera...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2015-01-05</td>\n",
              "      <td>2019-08-28</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1, PHASE2</td>\n",
              "      <td>176</td>\n",
              "      <td>Solid Tumors, Head and Neck Cancer, Lung Cance...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Incyte Corporation</td>\n",
              "      <td>The purpose of this study is to explore the sa...</td>\n",
              "      <td>Inclusion Criteria: * Male or female subjects,...</td>\n",
              "      <td>Phase 1 : Number of Treatment-Emergent Adverse...</td>\n",
              "      <td>Phase 1: Objective Response Rate (ORR) as Dete...</td>\n",
              "      <td>DRUG:MEDI4736 | DRUG:INCB024360</td>\n",
              "      <td>1461</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>35</th>\n",
              "      <td>NCT00910676</td>\n",
              "      <td>Study About Preventive Treatment of Folliculit...</td>\n",
              "      <td>Phase II Multicentric Study About Preventive T...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2007-10</td>\n",
              "      <td>2009-03</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>30</td>\n",
              "      <td>Metastatic Colorectal Cancer, Non-Small-Cell L...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Centre Oscar Lambret</td>\n",
              "      <td>Patients will receive local prophylactic treat...</td>\n",
              "      <td>Inclusion Criteria: * Indication of Cetuximab ...</td>\n",
              "      <td>To reduce by 30 % the frequency of folliculiti...</td>\n",
              "      <td>To assess the frequency of grade I, II and III...</td>\n",
              "      <td>DRUG:Diprosone</td>\n",
              "      <td>598</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>36</th>\n",
              "      <td>NCT03871205</td>\n",
              "      <td>Neoantigen-primed DC Vaccines Therapy for Refr...</td>\n",
              "      <td>A Phase I Study on the Safety and the Efficacy...</td>\n",
              "      <td>UNKNOWN</td>\n",
              "      <td>2019-04-01</td>\n",
              "      <td>2020-06-30</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>30</td>\n",
              "      <td>Carcinoma, Non-Small Cell Lung, Carcinoma, Sma...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>70 Years</td>\n",
              "      <td>Shenzhen People's Hospital</td>\n",
              "      <td>Various of immunotherapies are now widely appl...</td>\n",
              "      <td>Inclusion Criteria: * Age â‰¥18 years â‰¤ 70 years...</td>\n",
              "      <td>Incidence of Treatment-Emergent Adverse Events...</td>\n",
              "      <td>Objective Response Rate | Overall Survival (OS...</td>\n",
              "      <td>BIOLOGICAL:Neoantigen loaded DC vaccine</td>\n",
              "      <td>1077</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>37</th>\n",
              "      <td>NCT04311710</td>\n",
              "      <td>A Study Evaluating the Drug Levels of Iplimuma...</td>\n",
              "      <td>A Phase 1/2 Pharmacokinetic Multi-tumor Study ...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2020-06-25</td>\n",
              "      <td>2021-01-14</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>21</td>\n",
              "      <td>Tumor</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Bristol-Myers Squibb</td>\n",
              "      <td>A study evaluating the drug levels of ipilimum...</td>\n",
              "      <td>For more information regarding Bristol-Myers S...</td>\n",
              "      <td>Part 1 Arm A: Average concentration of ipilimu...</td>\n",
              "      <td>Part 1 Arm B: Average concentration of ipilimu...</td>\n",
              "      <td>DRUG:ipilimumab | DRUG:nivolumab | DRUG:ENHANZ...</td>\n",
              "      <td>1406</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>38</th>\n",
              "      <td>NCT07006727</td>\n",
              "      <td>Phase I Study of [225Ac]Ac-ETN029 in Patients ...</td>\n",
              "      <td>A Phase I, Open-label, Multi-center Study to E...</td>\n",
              "      <td>RECRUITING</td>\n",
              "      <td>2025-10-16</td>\n",
              "      <td>2031-06-17</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>96</td>\n",
              "      <td>Small Cell Lung Carcinoma, Large Cell Neuroend...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>100 Years</td>\n",
              "      <td>Novartis Pharmaceuticals</td>\n",
              "      <td>The purpose of this study is to evaluate the s...</td>\n",
              "      <td>Inclusion Criteria: * Age â‰¥ 18 years old * Pat...</td>\n",
              "      <td>Number of patients with dose limiting toxiciti...</td>\n",
              "      <td>Overall response rate (ORR) | Disease control ...</td>\n",
              "      <td>DRUG:225Ac-ETN029 | DRUG:111In-ETN029</td>\n",
              "      <td>2351</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>39</th>\n",
              "      <td>NCT04306900</td>\n",
              "      <td>TTX-030 in Combination With Immunotherapy and/...</td>\n",
              "      <td>Phase 1/1b Study to Evaluate the Safety and Ac...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2020-03-30</td>\n",
              "      <td>2022-11-30</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>185</td>\n",
              "      <td>Solid Tumor, Adult</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>110 Years</td>\n",
              "      <td>Trishula Therapeutics, Inc.</td>\n",
              "      <td>This is a phase 1/1b study of TTX-030 in combi...</td>\n",
              "      <td>Abbreviated Inclusion Criteria: 1. Age 18 year...</td>\n",
              "      <td>Number of Participants Who Experienced Dose-Li...</td>\n",
              "      <td>Confirmed Objective Response Rate (ORR) | Best...</td>\n",
              "      <td>COMBINATION_PRODUCT:TTX-030, budigalimab and m...</td>\n",
              "      <td>820</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>40</th>\n",
              "      <td>NCT01487499</td>\n",
              "      <td>Bronchoscopic Intratumoral Chemotherapy for Sm...</td>\n",
              "      <td>Bronchoscopic Intratumoral Chemotherapy for Sm...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2011-12</td>\n",
              "      <td>2015-03</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE3</td>\n",
              "      <td>4</td>\n",
              "      <td>Small Cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>University of Florida</td>\n",
              "      <td>This project proposes to use bronchoscopic int...</td>\n",
              "      <td>Inclusion Criteria: Competent adult English sp...</td>\n",
              "      <td>Solid Tumor Growth After Completion of Interve...</td>\n",
              "      <td>Progression-free Survival | Overall Survival</td>\n",
              "      <td>DRUG:Cisplatin</td>\n",
              "      <td>621</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>41</th>\n",
              "      <td>NCT05450692</td>\n",
              "      <td>A Phase III Study of Ceralasertib Plus Durvalu...</td>\n",
              "      <td>A Phase III, Open-label, Randomised, Multicent...</td>\n",
              "      <td>ACTIVE_NOT_RECRUITING</td>\n",
              "      <td>2022-09-15</td>\n",
              "      <td>2025-10-06</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE3</td>\n",
              "      <td>594</td>\n",
              "      <td>Advanced or Metastatic Non-Small Cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>130 Years</td>\n",
              "      <td>AstraZeneca</td>\n",
              "      <td>This study will assess the efficacy and safety...</td>\n",
              "      <td>Inclusion Criteria: * Histologically or cytolo...</td>\n",
              "      <td>Overall Survival (OS)</td>\n",
              "      <td>Progression-Free Survival (PFS) | Objective Re...</td>\n",
              "      <td>DRUG:Ceralasertib | DRUG:Durvalumab | DRUG:Doc...</td>\n",
              "      <td>2348</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>42</th>\n",
              "      <td>NCT01064466</td>\n",
              "      <td>Pharmacogenomics ANDA SNP Clinical Study - Eto...</td>\n",
              "      <td>Explore the Relationship Between Single Nucleo...</td>\n",
              "      <td>ACTIVE_NOT_RECRUITING</td>\n",
              "      <td>2025-07-16</td>\n",
              "      <td>2026-11-18</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2, PHASE3</td>\n",
              "      <td>600</td>\n",
              "      <td>Small Cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>24 Years</td>\n",
              "      <td>64 Years</td>\n",
              "      <td>Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigat...</td>\n",
              "      <td>Explore the relationship between drug target t...</td>\n",
              "      <td>* Select 600 Small Cell Lung Cancer Patients w...</td>\n",
              "      <td>Find Etoposide Drug Targets' SNP Genotypes whi...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DRUG:ETOPOSIDE - Usual | DRUG:ETOPOSIDE - Study</td>\n",
              "      <td>1499</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43</th>\n",
              "      <td>NCT00375245</td>\n",
              "      <td>Rapamycin With Grapefruit Juice for Advanced M...</td>\n",
              "      <td>A Phase Ib Study Administering Rapamycin (Siro...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2006-09</td>\n",
              "      <td>2009-05</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>41</td>\n",
              "      <td>Tumors, Neoplasm Metastasis</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>University of Chicago</td>\n",
              "      <td>The purpose of this study is to determine the ...</td>\n",
              "      <td>Inclusion Criteria: * Histologically confirmed...</td>\n",
              "      <td>Pharmacokinetic interaction</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DRUG:Rapamycin (sirolimus) | OTHER:Grapefruit ...</td>\n",
              "      <td>2933</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>44</th>\n",
              "      <td>NCT00475657</td>\n",
              "      <td>Pemetrexed and Cisplatin as Treatment in Small...</td>\n",
              "      <td>Phase II Study of Pemetrexed Plus Cisplatin in...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2007-10</td>\n",
              "      <td>2008-04</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>5</td>\n",
              "      <td>Small Cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Eli Lilly and Company</td>\n",
              "      <td>The purpose of this study is to determine if c...</td>\n",
              "      <td>Inclusion Criteria: * Histologic or cytologic ...</td>\n",
              "      <td>Overall Response Rate</td>\n",
              "      <td>Overall Survival | Progression Free Survival |...</td>\n",
              "      <td>DRUG:pemetrexed | DRUG:cisplatin</td>\n",
              "      <td>2010</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>45</th>\n",
              "      <td>NCT01944137</td>\n",
              "      <td>Improving Care After Chemotherapy</td>\n",
              "      <td>Improving Care After Chemotherapy</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2013-09</td>\n",
              "      <td>2014-11</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NaN</td>\n",
              "      <td>120</td>\n",
              "      <td>Non-small Cell Lung Cancer, Colorectal Cancer,...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Massachusetts General Hospital</td>\n",
              "      <td>The main purpose of this study is to examine c...</td>\n",
              "      <td>Inclusion Criteria: * Adult (age 18 or older) ...</td>\n",
              "      <td>Change from baseline (i.e. first chemotherapy ...</td>\n",
              "      <td>Change from baseline (i.e. first chemotherapy ...</td>\n",
              "      <td>OTHER:Nursing Intervention</td>\n",
              "      <td>531</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>46</th>\n",
              "      <td>NCT03501056</td>\n",
              "      <td>Study of Activated Cytokine-induced Killer Arm...</td>\n",
              "      <td>Phase II Randomized Comparison Clinical Trial ...</td>\n",
              "      <td>WITHDRAWN</td>\n",
              "      <td>2018-03-27</td>\n",
              "      <td>2020-05-25</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>0</td>\n",
              "      <td>Advanced Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>75 Years</td>\n",
              "      <td>Fuda Cancer Hospital, Guangzhou</td>\n",
              "      <td>This is a phase II Randomized comparison clini...</td>\n",
              "      <td>Inclusion Criteria: * 18-75 years old * The pa...</td>\n",
              "      <td>Objective response rate</td>\n",
              "      <td>Progression-free survival | Time tumor progres...</td>\n",
              "      <td>BIOLOGICAL:Activated CIK and CD3-MUC1 Bispecif...</td>\n",
              "      <td>2631</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>47</th>\n",
              "      <td>NCT00759824</td>\n",
              "      <td>A Phase II Study of Doxorubicin, Cyclophospham...</td>\n",
              "      <td>A Phase II Study of Doxorubicin, Cyclophospham...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2008-09</td>\n",
              "      <td>2013-12</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>64</td>\n",
              "      <td>Small Cell Lung Carcinoma</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>European Lung Cancer Working Party</td>\n",
              "      <td>The primary aim of this study is to determine ...</td>\n",
              "      <td>Inclusion Criteria: * Histological or cytologi...</td>\n",
              "      <td>Six-months progression-free survival</td>\n",
              "      <td>Survival | Response rate | Toxicity</td>\n",
              "      <td>DRUG:Adriamycin, cyclophosphamide, vindesine, ...</td>\n",
              "      <td>1962</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>48</th>\n",
              "      <td>NCT00621361</td>\n",
              "      <td>Phase I Safety and Tolerability Study of Cedir...</td>\n",
              "      <td>A Phase I, Multi-Centre, Open-Label, Dose Sele...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2008-02</td>\n",
              "      <td>2009-08</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>62</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>AstraZeneca</td>\n",
              "      <td>This study is to assess the safety and tolerab...</td>\n",
              "      <td>Inclusion Criteria: * Cancer diagnosis and sta...</td>\n",
              "      <td>Assess the safety and tolerability of Cedirani...</td>\n",
              "      <td>Preliminary efficacy assessment of Cediranib i...</td>\n",
              "      <td>DRUG:AZD2171 | DRUG:Etoposide | DRUG:Cisplatin</td>\n",
              "      <td>606</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>49</th>\n",
              "      <td>NCT06749691</td>\n",
              "      <td>Liposomal Irinotecan and Apatinib in ES-SCLC</td>\n",
              "      <td>Study of Liposomal Irinotecan Combined with Ap...</td>\n",
              "      <td>RECRUITING</td>\n",
              "      <td>2024-12-28</td>\n",
              "      <td>2027-12</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>30</td>\n",
              "      <td>Small Cell Lung Cancer Extensive Stage</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>75 Years</td>\n",
              "      <td>Second Affiliated Hospital, School of Medicine...</td>\n",
              "      <td>The purpose of this study is to observe the ef...</td>\n",
              "      <td>Inclusion Criteria: 1. Age range of 18-75 year...</td>\n",
              "      <td>Progression-Free-Survival rate at 6 months</td>\n",
              "      <td>ORR | mPFS | mOS</td>\n",
              "      <td>DRUG:Liposomal Irinotecan and Apatinib</td>\n",
              "      <td>798</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>50</th>\n",
              "      <td>NCT01588821</td>\n",
              "      <td>Cabozantinib in Advanced Solid Malignancies</td>\n",
              "      <td>Phase II Trial of Cabozantinib (XL184) in Pati...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2012-06</td>\n",
              "      <td>2017-01</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>37</td>\n",
              "      <td>Lung Cancer, Solid Tumor (Not Breast or Prosta...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Massachusetts General Hospital</td>\n",
              "      <td>This research study is a Phase II clinical tri...</td>\n",
              "      <td>Inclusion Criteria: * Histologic or cytologic ...</td>\n",
              "      <td>Number of Participants With Bone Bio-marker Re...</td>\n",
              "      <td>Number of Patients With Skeletal-related Event...</td>\n",
              "      <td>DRUG:Cabozantinib</td>\n",
              "      <td>1096</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>51</th>\n",
              "      <td>NCT03361228</td>\n",
              "      <td>A Study to Evaluate the Safety, Tolerability, ...</td>\n",
              "      <td>An Open-Label, Multicenter, Nonrandomized, Dos...</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>2018-03-01</td>\n",
              "      <td>2019-03-30</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1, PHASE2</td>\n",
              "      <td>5</td>\n",
              "      <td>Solid Tumors</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Incyte Corporation</td>\n",
              "      <td>The purpose of this study is to assess the saf...</td>\n",
              "      <td>Inclusion Criteria: * For Phase 1, subjects wi...</td>\n",
              "      <td>Phase 1 Only: Safety and Tolerability of INCB0...</td>\n",
              "      <td>Phase 2 Only: Safety and Tolerability of INCB0...</td>\n",
              "      <td>DRUG:INCB001158 | DRUG:Epacadostat | DRUG:Pemb...</td>\n",
              "      <td>2036</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>52</th>\n",
              "      <td>NCT02281214</td>\n",
              "      <td>NGS Genome Analysis in Personalisation of Lung...</td>\n",
              "      <td>Genome Analysis by Next Generation Sequencing ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2014-10-24</td>\n",
              "      <td>2014-11-17</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>NaN</td>\n",
              "      <td>165</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Centre Georges Francois Leclerc</td>\n",
              "      <td>The identification of driver mutations in the ...</td>\n",
              "      <td>Inclusion Criteria: * patients of bronchial ad...</td>\n",
              "      <td>search for EGFR, KRAS, BRAF, PIK3CA, HER2, ERB...</td>\n",
              "      <td>comparison of genome profiles (mutations and r...</td>\n",
              "      <td>OTHER:blood sample, biopsy</td>\n",
              "      <td>746</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>53</th>\n",
              "      <td>NCT05538130</td>\n",
              "      <td>A Study to Learn About the Study Medicine Call...</td>\n",
              "      <td>A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-077...</td>\n",
              "      <td>RECRUITING</td>\n",
              "      <td>2022-11-30</td>\n",
              "      <td>2027-02-02</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>124</td>\n",
              "      <td>Melanoma, Glioma, Thyroid Cancer, Non-Small Ce...</td>\n",
              "      <td>...</td>\n",
              "      <td>16 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Pfizer</td>\n",
              "      <td>The purpose of this clinical trial is to learn...</td>\n",
              "      <td>Inclusion Criteria: * Diagnosis of advanced/me...</td>\n",
              "      <td>Number of participants with dose limiting toxi...</td>\n",
              "      <td>Number of participants with treatment-emergent...</td>\n",
              "      <td>DRUG:PF-07799544 | DRUG:PF-07799933 | DRUG:enc...</td>\n",
              "      <td>986</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>54</th>\n",
              "      <td>NCT00967577</td>\n",
              "      <td>177Lu-J591 Antibody in Patients With Nonprosta...</td>\n",
              "      <td>177Lu Radiolabeled Monoclonal Antibody HuJ591-...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2009-07</td>\n",
              "      <td>2018-06</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>20</td>\n",
              "      <td>Kidney Cancer, Head and Neck Cancer, Breast Ca...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Weill Medical College of Cornell University</td>\n",
              "      <td>The purpose of this study is to evaluate chang...</td>\n",
              "      <td>Inclusion Criteria: * Histologically, or cytol...</td>\n",
              "      <td>Change in tumor perfusion as based on Dynamic ...</td>\n",
              "      <td>Changes in response rate using Response evalua...</td>\n",
              "      <td>DRUG:177Lu-J591</td>\n",
              "      <td>3265</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>55</th>\n",
              "      <td>NCT02200081</td>\n",
              "      <td>Randomized Study of Maintenance Therapy With M...</td>\n",
              "      <td>Randomized Clinical Study of Maintenance Thera...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2014-03</td>\n",
              "      <td>2016-11</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>103</td>\n",
              "      <td>Small Cell Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Mologen AG</td>\n",
              "      <td>Evaluation of efficacy and safety of MGN1703 a...</td>\n",
              "      <td>1. Male and female patients with extensive dis...</td>\n",
              "      <td>Overall survival (OS)</td>\n",
              "      <td>OS1</td>\n",
              "      <td>DRUG:MGN1703 | OTHER:Standard of care</td>\n",
              "      <td>1492</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>56</th>\n",
              "      <td>NCT00570401</td>\n",
              "      <td>Dasatinib in Treating Patients With Advanced L...</td>\n",
              "      <td>A Phase 2 Trial of Dasatinib in Patients With ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2006-06</td>\n",
              "      <td>2011-09</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>22</td>\n",
              "      <td>Lung Cancer</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>120 Years</td>\n",
              "      <td>Memorial Sloan Kettering Cancer Center</td>\n",
              "      <td>RATIONALE: Dasatinib may stop the growth of tu...</td>\n",
              "      <td>DISEASE CHARACTERISTICS: * Pathologically conf...</td>\n",
              "      <td>Determine the Overall Objective Response</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DRUG:dasatinib</td>\n",
              "      <td>2450</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>57</th>\n",
              "      <td>NCT00496860</td>\n",
              "      <td>Safety and Efficacy Study of ALT-801 to Treat ...</td>\n",
              "      <td>Phase I Study of ALT-801 in Patients With Prog...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>2007-05</td>\n",
              "      <td>2009-10</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>26</td>\n",
              "      <td>Progressive Metastatic Malignancies</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Altor BioScience</td>\n",
              "      <td>This is a Phase 1, open-labeled, non-randomize...</td>\n",
              "      <td>ENTRY CRITERIA: DISEASE CHARACTERISTICS: * Loc...</td>\n",
              "      <td>The Safety and Toxicity of ALT-801 in Patients...</td>\n",
              "      <td>Clinical Antitumor Response to ALT-801 | ALT-8...</td>\n",
              "      <td>BIOLOGICAL:ALT-801</td>\n",
              "      <td>2425</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>58</th>\n",
              "      <td>NCT06400472</td>\n",
              "      <td>A Study of LY4170156 in Participants With Sele...</td>\n",
              "      <td>A First-in-Human, Phase 1a/1b Trial to Assess ...</td>\n",
              "      <td>RECRUITING</td>\n",
              "      <td>2024-05-20</td>\n",
              "      <td>2027-02</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>495</td>\n",
              "      <td>Ovarian Neoplasms, Endometrial Neoplasms, Uter...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Eli Lilly and Company</td>\n",
              "      <td>The purpose of this study is to find out wheth...</td>\n",
              "      <td>Inclusion Criteria: * Have one of the followin...</td>\n",
              "      <td>Phase 1a: To determine the recommended phase 2...</td>\n",
              "      <td>To characterize the pharmacokinetics (PK) prop...</td>\n",
              "      <td>DRUG:LY4170156 | DRUG:bevacizumab | DRUG:carbo...</td>\n",
              "      <td>1251</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>59</th>\n",
              "      <td>NCT07106528</td>\n",
              "      <td>Organoid-guided vs Topotecan Therapy in Relaps...</td>\n",
              "      <td>Organoid-Based Drug Sensitivity Model Guided P...</td>\n",
              "      <td>NOT_YET_RECRUITING</td>\n",
              "      <td>2025-08</td>\n",
              "      <td>2027-12</td>\n",
              "      <td>INTERVENTIONAL</td>\n",
              "      <td>PHASE2, PHASE3</td>\n",
              "      <td>128</td>\n",
              "      <td>Extensive-stage Small Cell Lung Cancer (ES-SCL...</td>\n",
              "      <td>...</td>\n",
              "      <td>18 Years</td>\n",
              "      <td>NaN</td>\n",
              "      <td>Peking Union Medical College Hospital</td>\n",
              "      <td>This study aims to provide personalized treatm...</td>\n",
              "      <td>Inclusion Criteria: 1. Aged 18 years or older....</td>\n",
              "      <td>Progression-Free Survival (PFS)</td>\n",
              "      <td>Overall Survival (OS) | Objective Response Rat...</td>\n",
              "      <td>DRUG:Organoid Drug Sensitivity Testing-Guided ...</td>\n",
              "      <td>2304</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>60 rows Ã— 21 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-ed1effe5-8ba8-41a7-a6a0-afe51fe71738')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-ed1effe5-8ba8-41a7-a6a0-afe51fe71738 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-ed1effe5-8ba8-41a7-a6a0-afe51fe71738');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-b05d4280-82b4-4489-ac64-8ed89dbb9d40\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-b05d4280-82b4-4489-ac64-8ed89dbb9d40')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-b05d4280-82b4-4489-ac64-8ed89dbb9d40 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_327b62a3-4950-4ad4-8463-e00ae6815a78\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('trials_df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_327b62a3-4950-4ad4-8463-e00ae6815a78 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('trials_df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "trials_df"
            }
          },
          "metadata": {},
          "execution_count": 6
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "pd.reset_option('display.max_colwidth')\n",
        "pd.reset_option('display.max_rows')"
      ],
      "metadata": {
        "id": "uRlbepVLTj0A"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "pd.set_option(\"display.max_rows\", None)"
      ],
      "metadata": {
        "id": "9n6caocxTk3g"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "pd.set_option('display.max_colwidth', None)"
      ],
      "metadata": {
        "id": "Ova81lgbTk6A"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# trials_df[[\"NCT_ID\",\"Brief_Summary\",\"Eligibility\",\"eligibility_json\"]].loc[59]"
      ],
      "metadata": {
        "id": "tQ3ooAmnTk8o"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "_1HLevssQSZB"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "elgibiltiy_df = pd.read_csv(\"./data/patiens_trials_elgibiltiy.csv\")"
      ],
      "metadata": {
        "id": "Q6EvO-iDTk-w"
      },
      "execution_count": 24,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "elgibiltiy_df.loc[elgibiltiy_df[\"trial_id\"] == \"NCT03346728\", \"trial_id\"] = \"NCT03361228\""
      ],
      "metadata": {
        "id": "huiel50JTlBQ"
      },
      "execution_count": 8,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "elgibiltiy_df = elgibiltiy_df.rename(columns={\"trial_id\": \"NCT_ID\"})"
      ],
      "metadata": {
        "id": "uluIeAKsTlDw"
      },
      "execution_count": 9,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "elgibiltiy_df[\"unique_patient_id\"] = elgibiltiy_df[\"NCT_ID\"] + \"_\" + elgibiltiy_df[\"patient_id\"]"
      ],
      "metadata": {
        "id": "2o2M-mgHTu5l"
      },
      "execution_count": 10,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "elgibiltiy_df = elgibiltiy_df.merge(\n",
        "    trials_df[[\"NCT_ID\", \"eligibility_json\"]],\n",
        "    on=\"NCT_ID\",\n",
        "    how=\"left\"\n",
        ")"
      ],
      "metadata": {
        "id": "yPHuMGobTu8b"
      },
      "execution_count": 11,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "elgibiltiy_df.sample(5)"
      ],
      "metadata": {
        "id": "dy7SeR2ETu_N",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 293
        },
        "outputId": "da025b69-e750-4d2e-c092-5a5831c59887"
      },
      "execution_count": 14,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "          NCT_ID patient_id  \\\n",
              "231  NCT01951469       P002   \n",
              "379  NCT04311710       P010   \n",
              "686  NCT02772107       P012   \n",
              "383  NCT07006727       P004   \n",
              "159  NCT06963502       P010   \n",
              "\n",
              "                                          patient_json  is_eligible  \\\n",
              "231  {\"age\":42,\"gender\":\"M\",\"diagnosis\":\"stage IV N...         True   \n",
              "379  {\"age\":61,\"gender\":\"F\",\"trial_part\":\"Part 2, A...         True   \n",
              "686  {\"age\":58,\"gender\":\"F\",\"sclc_stage\":\"Extensive...         True   \n",
              "383  {\"age\": 45, \"diagnosis\": \"LCNEC of the lung\", ...         True   \n",
              "159  {\"age\":60,\"gender\":\"F\",\"diagnosis\":\"metastatic...         True   \n",
              "\n",
              "                                             reasoning unique_patient_id  \\\n",
              "231  Eligible: EGFR mutant NSCLC with 1-2 brain les...  NCT01951469_P002   \n",
              "379  Eligible (NSCLC): Although ALK-positive, the m...  NCT04311710_P010   \n",
              "686  Eligible: Extensive-stage SCLC, ECOG 1, LFTs u...  NCT02772107_P012   \n",
              "383  Eligible (LCNEC, DE): LCNEC is an inclusion on...  NCT07006727_P004   \n",
              "159  Eligible: textbook KRAS G12C NSCLC, ECOG 0, no...  NCT06963502_P010   \n",
              "\n",
              "                                      eligibility_json  \n",
              "231  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "379  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "686  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "383  {'trial_id': None, 'trial_category': 'therapeu...  \n",
              "159  {'trial_id': None, 'trial_category': 'therapeu...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-5141e367-dbdd-4a5b-885c-69d334c3b044\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>NCT_ID</th>\n",
              "      <th>patient_id</th>\n",
              "      <th>patient_json</th>\n",
              "      <th>is_eligible</th>\n",
              "      <th>reasoning</th>\n",
              "      <th>unique_patient_id</th>\n",
              "      <th>eligibility_json</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>231</th>\n",
              "      <td>NCT01951469</td>\n",
              "      <td>P002</td>\n",
              "      <td>{\"age\":42,\"gender\":\"M\",\"diagnosis\":\"stage IV N...</td>\n",
              "      <td>True</td>\n",
              "      <td>Eligible: EGFR mutant NSCLC with 1-2 brain les...</td>\n",
              "      <td>NCT01951469_P002</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>379</th>\n",
              "      <td>NCT04311710</td>\n",
              "      <td>P010</td>\n",
              "      <td>{\"age\":61,\"gender\":\"F\",\"trial_part\":\"Part 2, A...</td>\n",
              "      <td>True</td>\n",
              "      <td>Eligible (NSCLC): Although ALK-positive, the m...</td>\n",
              "      <td>NCT04311710_P010</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>686</th>\n",
              "      <td>NCT02772107</td>\n",
              "      <td>P012</td>\n",
              "      <td>{\"age\":58,\"gender\":\"F\",\"sclc_stage\":\"Extensive...</td>\n",
              "      <td>True</td>\n",
              "      <td>Eligible: Extensive-stage SCLC, ECOG 1, LFTs u...</td>\n",
              "      <td>NCT02772107_P012</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>383</th>\n",
              "      <td>NCT07006727</td>\n",
              "      <td>P004</td>\n",
              "      <td>{\"age\": 45, \"diagnosis\": \"LCNEC of the lung\", ...</td>\n",
              "      <td>True</td>\n",
              "      <td>Eligible (LCNEC, DE): LCNEC is an inclusion on...</td>\n",
              "      <td>NCT07006727_P004</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>159</th>\n",
              "      <td>NCT06963502</td>\n",
              "      <td>P010</td>\n",
              "      <td>{\"age\":60,\"gender\":\"F\",\"diagnosis\":\"metastatic...</td>\n",
              "      <td>True</td>\n",
              "      <td>Eligible: textbook KRAS G12C NSCLC, ECOG 0, no...</td>\n",
              "      <td>NCT06963502_P010</td>\n",
              "      <td>{'trial_id': None, 'trial_category': 'therapeu...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-5141e367-dbdd-4a5b-885c-69d334c3b044')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-5141e367-dbdd-4a5b-885c-69d334c3b044 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-5141e367-dbdd-4a5b-885c-69d334c3b044');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-089f3c75-c3d5-4b7f-a315-352988c6b0e7\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-089f3c75-c3d5-4b7f-a315-352988c6b0e7')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-089f3c75-c3d5-4b7f-a315-352988c6b0e7 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"elgibiltiy_df\",\n  \"rows\": 5,\n  \"fields\": [\n    {\n      \"column\": \"NCT_ID\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"NCT04311710\",\n          \"NCT06963502\",\n          \"NCT02772107\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"patient_id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"P010\",\n          \"P004\",\n          \"P002\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"patient_json\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"{\\\"age\\\":61,\\\"gender\\\":\\\"F\\\",\\\"trial_part\\\":\\\"Part 2, Arm A\\\",\\\"diagnosis\\\":\\\"Stage IV NSCLC\\\",\\\"histology_confirmed\\\":true,\\\"prior_treatment_nsclc\\\":\\\"Failed chemo\\\",\\\"ecog_ps\\\":0,\\\"karnofsky_ps_percent\\\":100,\\\"study_drug_allergy\\\":false,\\\"hcc_exclusions_apply\\\":false,\\\"nsclc_molecular_status\\\":\\\"EGFR wild type, ALK positive but TKI resistant\\\"}\",\n          \"{\\\"age\\\":60,\\\"gender\\\":\\\"F\\\",\\\"diagnosis\\\":\\\"metastatic NSCLC\\\",\\\"kras_status\\\":\\\"G12C\\\",\\\"other_drivers\\\":\\\"none\\\",\\\"prior_kras_g12c_inhibitor\\\":false,\\\"ecog\\\":0,\\\"measurable_disease\\\":true,\\\"brain_mets\\\":\\\"none\\\",\\\"unresolved_tox_gte2\\\":false,\\\"uncontrolled_effusion\\\":false,\\\"spinal_cord_compression\\\":false,\\\"ild_history\\\":false,\\\"active_autoimmune\\\":false,\\\"severe_cardiac\\\":false,\\\"child_pugh\\\":\\\"A\\\",\\\"can_swallow_pills\\\":true,\\\"contraception_compliant\\\":true,\\\"pregnant\\\":false}\",\n          \"{\\\"age\\\":58,\\\"gender\\\":\\\"F\\\",\\\"sclc_stage\\\":\\\"Extensive-Stage\\\",\\\"measurable_disease\\\":true,\\\"brain_metastases\\\":false,\\\"ecog_performance_status\\\":1,\\\"anc_ul\\\":2500,\\\"platelets_ul\\\":120000,\\\"hemoglobin_g_dl\\\":9.5,\\\"ast_alt_xuln\\\":4.0,\\\"liver_malig_cause\\\":true,\\\"total_serum_bilirubin_xuln\\\":1.5,\\\"serum_creatinine_xuln\\\":1.5,\\\"chemo_to_random_weeks\\\":7,\\\"uncontrolled_intercurrent_illness\\\":false,\\\"leptomeningeal_involvement\\\":false,\\\"aids_or_hiv_on_haart\\\":false,\\\"investigational_agents\\\":false,\\\"pregnant_or_breastfeeding\\\":false,\\\"contraception_used\\\":true}\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"is_eligible\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          true\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"reasoning\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Eligible (NSCLC): Although ALK-positive, the molecular status specifies it is TKI-resistant, meaning it is **not sensitive to available targeted inhibitor therapy**, thus making the patient eligible.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"unique_patient_id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"NCT04311710_P010\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"eligibility_json\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"{'trial_id': None, 'trial_category': 'therapeutic_interventional', 'age': {'min': 18, 'max': None}, 'region_specific_age': {'japan_min': None}, 'inclusion': {'disease': {'confirmed_by': 'histology', 'cancer_type': '', 'histology_subtype': '', 'stage': 'IV', 'stage_list': ['IV'], 'metastatic': True, 'measurable_disease_recist': None, 'biomarker_required': []}, 'performance_status': {'scale': 'ECOG', 'min': 0, 'max': 1}, 'life_expectancy_weeks': None, 'prior_therapy': {'required': [], 'allowed': [], 'disallowed': [], 'max_lines_systemic': None, 'washout_weeks': {'chemotherapy': None, 'targeted_therapy': None, 'immunotherapy': None, 'investigational': None, 'radiation': None, 'major_surgery': None}}, 'brain_metastases': None, 'brain_mets_stable_duration_weeks': None, 'organ_function': {'anc': None, 'platelets': None, 'hemoglobin_g_per_dl': None, 'creatinine_clearance_ml_min': None, 'bilirubin_x_uln': None, 'ast_alt_x_uln': None, 'albumin_g_per_dl': None}, 'cardiac': {'qtcf_ms_max': None, 'recent_mi_months_exclusion': None, 'nyha_class_max': None, 'lvef_percent_min': None}, 'contraception_required': True, 'other_inclusions': ['Histologically confirmed urothelial carcinoma for Part 1 Arm A: Advanced/mUC', 'Histological confirmation of Hepatocellular Cancer (HCC) for Part 1 Arm A: Advanced HCC', 'Histologically confirmed stage IV or recurrent NSCLC for Part 2 Arm A: Metastatic NSCLC', 'Histological confirmation of Renal Cell Carcinoma (RCC) for Part 2 Arm B: Advanced or Metastatic RCC', 'Karnofsky performance status \\u2265 70% for RCC (Part 2 Arm B)']}, 'exclusion': {'pregnant_or_breastfeeding': None, 'active_cns_metastases': None, 'uncontrolled_intercurrent_illness': None, 'grade_2_or_higher_neuropathy': None, 'history_of': ['allergy or hypersensitivity to study drug components'], 'concurrent_medications_disallowed': [], 'other_exclusions': ['History of hepatic encephalopathy or evidence of portal hypertension for Advanced HCC', 'Active coinfection with hepatitis D virus infection in participants with HBV for Advanced HCC', 'Known ALK translocations and EGFR mutation sensitive to available targeted inhibitor therapy for Metastatic NSCLC']}}\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 14
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "elgibiltiy_df.to_csv(\"./data/patiens_trials_elgibiltiy_training_data.csv\", index=False)"
      ],
      "metadata": {
        "id": "luIenHM6TvBs"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "elgibiltiy_df = pd.read_csv(\"./data/patiens_trials_elgibiltiy_training_data.csv\")"
      ],
      "metadata": {
        "id": "jYSkOtjsVUgY"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "j0J-9zowUGQI"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "counts_df = elgibiltiy_df.groupby(\"NCT_ID\").size().reset_index(name=\"record_count\")\n",
        "# print(counts_df)"
      ],
      "metadata": {
        "id": "llRG22NxTlFw"
      },
      "execution_count": 17,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "unique_counts = counts_df[\"record_count\"].unique()\n",
        "print(f\"Patients per trial: {unique_counts[0]}\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "CpyjRKJIRc3O",
        "outputId": "8eb7fd92-4fac-4e49-ce0e-5a74443a8ad4"
      },
      "execution_count": 18,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Patients per trial: 15\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "elgibiltiy_df['is_eligible'].value_counts()"
      ],
      "metadata": {
        "id": "usvaVh91UH8n",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 178
        },
        "outputId": "6c721604-7ab4-4316-cc82-fc22839cba06"
      },
      "execution_count": 16,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "is_eligible\n",
              "True     467\n",
              "False    433\n",
              "Name: count, dtype: int64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>is_eligible</th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>True</th>\n",
              "      <td>467</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>False</th>\n",
              "      <td>433</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> int64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 16
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df =elgibiltiy_df.copy()\n",
        "\n",
        "def fix_json_column(col):\n",
        "    def convert(x):\n",
        "        # If already a dict â†’ dump to JSON\n",
        "        if isinstance(x, dict):\n",
        "            return json.dumps(x)\n",
        "\n",
        "        # Try JSON first\n",
        "        try:\n",
        "            return json.dumps(json.loads(x))\n",
        "        except:\n",
        "            pass\n",
        "\n",
        "        # Try Python dict format\n",
        "        try:\n",
        "            py_obj = ast.literal_eval(x)\n",
        "            return json.dumps(py_obj)\n",
        "        except Exception as e:\n",
        "            print(\"BAD JSON:\", x)\n",
        "            raise e\n",
        "\n",
        "    return col.apply(convert)\n",
        "\n",
        "\n",
        "df[\"patient_json\"] = fix_json_column(df[\"patient_json\"])\n",
        "df[\"eligibility_json\"] = fix_json_column(df[\"eligibility_json\"])\n"
      ],
      "metadata": {
        "id": "dXCXjAgsUKq5"
      },
      "execution_count": 19,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def make_example(row):\n",
        "    instruction = (\n",
        "        \"Decide whether the following patient is eligible for the given clinical trial, \"\n",
        "        \"and provide reasoning for your decision.\"\n",
        "    )\n",
        "\n",
        "    input_data = {\n",
        "        \"patient\": json.loads(row[\"patient_json\"]),\n",
        "        \"trial_eligibility\": json.loads(row[\"eligibility_json\"]),\n",
        "    }\n",
        "\n",
        "    output = {\n",
        "        \"is_eligible\": bool(row[\"is_eligible\"]),\n",
        "        \"reasoning\": row[\"reasoning\"]\n",
        "    }\n",
        "\n",
        "    return {\n",
        "        \"instruction\": instruction,\n",
        "        \"input\": input_data,\n",
        "        \"output\": output,\n",
        "    }\n",
        "\n",
        "examples = df.apply(make_example, axis=1).tolist()\n"
      ],
      "metadata": {
        "id": "d-Dtg_3GUODg"
      },
      "execution_count": 20,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install \"unsloth[colab-new] @ git+https://github.com/unslothai/unsloth.git\"\n",
        "!pip install --no-deps xformers trl peft accelerate bitsandbytes"
      ],
      "metadata": {
        "id": "BPMV6wHSUQRR"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from unsloth import FastLanguageModel\n",
        "import torch\n",
        "\n",
        "# Making 8B fit on T4\n",
        "model, tokenizer = FastLanguageModel.from_pretrained(\n",
        "    model_name=\"unsloth/Meta-Llama-3.1-8B-Instruct-bnb-4bit\",\n",
        "    max_seq_length=4096,\n",
        "    dtype=None,\n",
        "    load_in_4bit=True,\n",
        "\n",
        "    use_gradient_checkpointing=\"unsloth\",\n",
        ")\n",
        "\n",
        "model = FastLanguageModel.get_peft_model(\n",
        "    model,\n",
        "    r=32,              # lowered from 64 to save VRAM\n",
        "    target_modules=[\"q_proj\", \"k_proj\", \"v_proj\", \"o_proj\",\n",
        "                    \"gate_proj\", \"up_proj\", \"down_proj\"],\n",
        "    lora_alpha=16,\n",
        "    lora_dropout=0,\n",
        "    bias=\"none\",\n",
        "    use_gradient_checkpointing=\"unsloth\",\n",
        "    random_state=3407,\n",
        ")"
      ],
      "metadata": {
        "id": "DlLESVrAUSzD"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from datasets import Dataset\n",
        "\n",
        "# No split â€” use all data for training\n",
        "train_examples = examples\n",
        "\n",
        "# =====================================================\n",
        "# Formatting function\n",
        "# =====================================================\n",
        "\n",
        "def formatting_prompts_func(example):\n",
        "    messages = [\n",
        "        {\"role\": \"system\", \"content\": \"You are an expert in assessing eligibility for oncology clinical trials. Decide whether the patient is eligible and explain your reasoning step by step.\"},\n",
        "        {\"role\": \"user\", \"content\": example[\"instruction\"] + \"\\n\\nPatient data and trial criteria:\\n\" + json.dumps(example[\"input\"], indent=2)},\n",
        "        {\"role\": \"assistant\", \"content\": json.dumps(example[\"output\"], indent=2)}\n",
        "    ]\n",
        "\n",
        "    text = \"\".join(\n",
        "        f\"<|begin_of_text|><|start_header_id|>{msg['role']}<|end_header_id|>\\n\\n{msg['content']}<|eot_id|>\"\n",
        "        for msg in messages\n",
        "    ) + \"<|start_header_id|>assistant<|end_header_id|>\\n\\n\"\n",
        "\n",
        "    return {\"text\": text}\n",
        "\n",
        "# Build dataset\n",
        "train_dataset = Dataset.from_list([formatting_prompts_func(ex) for ex in train_examples])\n",
        "\n",
        "print(f\"Train size: {len(train_dataset)}\")\n",
        "\n",
        "\n",
        "# =====================================================\n",
        "# Training\n",
        "# =====================================================\n",
        "\n",
        "from trl import SFTTrainer\n",
        "from transformers import TrainingArguments\n",
        "\n",
        "trainer = SFTTrainer(\n",
        "    model=model,\n",
        "    tokenizer=tokenizer,\n",
        "    train_dataset=train_dataset,\n",
        "    dataset_text_field=\"text\",\n",
        "    max_seq_length=4096,\n",
        "    packing=True,\n",
        "    args=TrainingArguments(\n",
        "        per_device_train_batch_size=2,\n",
        "        gradient_accumulation_steps=4,\n",
        "        warmup_steps=10,\n",
        "        max_steps=90,\n",
        "        learning_rate=2e-4,\n",
        "        fp16=True,\n",
        "        bf16=False,\n",
        "        logging_steps=10,\n",
        "        save_strategy=\"steps\",\n",
        "        save_steps=30,\n",
        "        output_dir=\"/content/llama3.1-8b-clinical-eligibility\",\n",
        "        optim=\"adamw_8bit\",\n",
        "        seed=3407,\n",
        "        report_to=\"none\",\n",
        "    ),\n",
        ")"
      ],
      "metadata": {
        "id": "EkkvUP5yUZUM"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "trainer.train()"
      ],
      "metadata": {
        "id": "QhowiejZUbh9"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/drive')"
      ],
      "metadata": {
        "id": "KJAaACxWUc9-"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Final LoRA adapter saveing\n",
        "model.save_pretrained(\"/content/drive/MyDrive/Clinical_Trial_LLM/final_lora_adapter_3\")\n",
        "tokenizer.save_pretrained(\"/content/drive/MyDrive/Clinical_Trial_LLM/final_lora_adapter_3\")"
      ],
      "metadata": {
        "id": "A2vWWNu1UeX8"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install -q huggingface_hub transformers sentencepiece"
      ],
      "metadata": {
        "id": "FVPYFhY_UnNO"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from huggingface_hub import login\n",
        "from huggingface_hub import whoami\n",
        "\n",
        "login(\"your_hf_token\")\n",
        "print(whoami())"
      ],
      "metadata": {
        "id": "93KyuThNS8M8"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Loading LoRA adapter + base model\n",
        "\n",
        "model, tokenizer = FastLanguageModel.from_pretrained(\n",
        "    \"/content/drive/MyDrive/Clinical_Trial_LLM/final_lora_adapter_3\",\n",
        "    max_seq_length=4096,\n",
        "    dtype=None,           # will be float16 or bfloat16\n",
        "    load_in_4bit=True,    # load quantized first (saves RAM during merge)\n",
        ")\n",
        "\n",
        "# Enable native inference mode (needed before merging)\n",
        "FastLanguageModel.for_inference(model)"
      ],
      "metadata": {
        "id": "AR8mx8n3S8PN"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Merge and upload the FULL model\n",
        "\n",
        "# Merged 16-bit\n",
        "model.push_to_hub_merged(\n",
        "    \"ayham0010/LungTrial-Eligible\",\n",
        "    tokenizer,\n",
        "    save_method=\"merged_16bit\",\n",
        "    token=True,\n",
        ")"
      ],
      "metadata": {
        "id": "gUGIKFu4T0K7"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "0-rF3lopUA2I"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}